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PDT for the thoracic cavity provides a promising cancer treatment modality, but improvements in
treatment planning, particularly in PDT dosimetry, can be made to improve uniformity of light delivery.
When a cavity of arbitrary geometry is illuminated, the fluence increases due to multiple-scattered
photons, referred to as the Integrating Sphere Effect (ISE). Current pleural PDT treatment protocol at the
University of Pennsylvania monitors light fluence (hereafter simply fluence, measured in W/cm2) via
seven isotropic detectors sutured at different locations in thoracic cavity of a patient. This protocol
monitors light at discrete locations, but does not provide a measurement of fluence for the thoracic cavity
as a whole. Current calculation of light fluence includes direct light only and thus does not account for the
unique optical properties of each tissue type present, which in turn affects the accuracy of the calculated
light distribution in the surrounding tissue and, in turn, the overall cell death and treatment efficacy.
Treatment planning for pleural PDT can be improved, in part, by considering the contribution of scattered
light, which is affected by the two factors of geometry and in vivo optical properties. We expanded the
work by Willem Star in regards to the ISE in a spherical cavity. A series of Monte Carlo (MC) simulations
were run for semi-infinite planar, spherical, and ellipsoidal geometries for a range of optical properties.
The results of these simulations are compared to theory and numerical solutions for fluence in the cavity
and at the cavity-medium boundary. The development via MC simulations offers a general method of
calculating the required light fluence specialized to each patient, based on the treatment surface area.
The scattered fluence calculation is dependent on in vivo optical properties (μa and μs') of the tissues
treated. Diffuse reflectance and fluorescence spectroscopy methods are used to determine the optical
properties and oxygenation (reflectance measurements) and drug concentration (fluorescence
measurements) of different tissues in vivo, before and after treatment, in patients enrolled the Phase I
HPPH study ongoing at the University of Pennsylvania.
This work aims to provide the building blocks essential to pleural PDT treatment planning by more
accurately calculating the required fluence using a model that accounts for the effects of treatment
geometry and optical properties measured in vivo.
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ABSTRACT
PDT IN THE THORACIC CAVITY: SPECTROSCOPIC METHODS AND FLUENCE MODELING
FOR TREATMENT PLANNING
Julia L. Meo
Dr. Timothy C. Zhu
Dr. Jarod C. Finlay

PDT for the thoracic cavity provides a promising cancer treatment modality, but
improvements in treatment planning, particularly in PDT dosimetry, can be made to improve
uniformity of light delivery. When a cavity of arbitrary geometry is illuminated, the fluence
increases due to multiple-scattered photons, referred to as the Integrating Sphere Effect (ISE).
Current pleural PDT treatment protocol at the University of Pennsylvania monitors light fluence
(hereafter simply fluence, measured in W/cm2) via seven isotropic detectors sutured at different
locations in thoracic cavity of a patient. This protocol monitors light at discrete locations, but
does not provide a measurement of fluence for the thoracic cavity as a whole. Current
calculation of light fluence includes direct light only and thus does not account for the unique
optical properties of each tissue type present, which in turn affects the accuracy of the
calculated light distribution in the surrounding tissue and, in turn, the overall cell death and
treatment efficacy.
Treatment planning for pleural PDT can be improved, in part, by considering the
contribution of scattered light, which is affected by the two factors of geometry and in vivo
optical properties. We expanded the work by Willem Star in regards to the ISE in a spherical
cavity. A series of Monte Carlo (MC) simulations were run for semi-infinite planar, spherical, and
iii

ellipsoidal geometries for a range of optical properties. The results of these simulations are
compared to theory and numerical solutions for fluence in the cavity and at the cavity-medium
boundary. The development via MC simulations offers a general method of calculating the
required light fluence specialized to each patient, based on the treatment surface area.

The scatter fluence calculation is dependent on in vivo optical properties (µa and µs’) of the
tissues treated. Diffuse reflectance and fluorescence spectroscopy methods are used to
determine the optical properties and oxygenation (reflectance measurements) and drug
concentration (fluorescence measurements) of different tissues in vivo, before and after
treatment, in patients enrolled the Phase I HPPH study ongoing at the University of
Pennsylvania.
This work aims to provide the building blocks essential to pleural PDT treatment planning
by more accurately calculating the required fluence using a model that accounts for the effects
of treatment geometry and optical properties measured in vivo.
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Chapter 1

Introduction
1.1 Photodynamic Therapy
Photodynamic therapy (PDT) is a cancer treatment modality that consists of light, a
photosensitizing drug, and singlet oxygen, 1O2, to cause local cell damage as a method of killing
cancerous tissues. PDT has been applied to a wide variety of cancers including cancers of the
bladder[1-8], the prostate[9-24], and of the head and neck[25]. While still in development to
become a common cancer treatment, PDT is already FDA approved for skin[26-31],
esophageal[32], bladder [1-8], and ophthalmic cancers[33]. PDT is a localized treatment method,
unlike systemic chemotherapy, sparing healthy cells. Unlike radiation therapy, using ionizing
radiation, it does not cause long term cumulative damage to the patient as it does not appear to
target DNA [34]. The advantages of PDT are clear but much work needs to be done in optimizing
treatment doses, PDT delivery methods, and PDT dosimetry before it can become a standard
cancer treatment option to patients with a variety of malignancies.
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Current PDT treatment protocol for pleural PDT at the Hospital of the University of
Pennsylvania (UPHS) is to administer a photosensitizing drug to the patient, either systematically
at the appropriate time before surgery and light application. This is referred to as the drug-light
interval. Light at a drug specific wavelength is then administered to the cancerous region on the
patient’s body after the drug-light interval has passed. This light administration in combination
with the photosensitizer activates a reactive singlet oxygen species 1O2, causing local cell
damage thereby killing the cancerous tissue. At the UPHS, the fluence, or light dose, for pleural
PDT is administered at a predetermined dose and is not dependent on the unique qualities of
the patient for thoracic cavity treatment[35]. Fluence is monitored, in the instance of PDT for
the thoracic cavity, by isotropic detectors sutured to the patient’s thoracic cavity by the
surgeon. Once these detectors indicate the prescribed total light dose is reached, the light
source is turned off, and PDT is considered complete.

1.1.1 Photosensitizers
The development of photosensitizers is ongoing, with sensitivity designed to be in the
“therapeutic window” (650-850 nm) where the hemoglobin spectrum does not dominate (see
Figure 1.1). In this window, for light sources whose wavelength is between 650-850 nm, light
penetrates deeper into the tissue as optical absorption is lower than in other parts of the
spectrum, reaching a greater area of tissue and causing more cell death overall. In this work, we
consider two photosensitizers: benzoporphyrin derivative monoacid (BPD) and 2-[1hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH).

2

Figure 1.1: Molar absorption coefficients of common absorbents.
Note the relative dip in absorption between 600 and 800 nm; this is the “therapeutic window”.

As Allison et al. state in their review of photosensitizers
photosensitizers[36],, the ideal photosensitizer
would possess low toxicity, reliable activation at longer wavelengths (above 630 nm), short
sensitivity to sunlight, low
ow cost, and good availability. The first generation of photosensitizers
was porphyrin based, as is the BPD used here in the canine study. Porphyrin based
photosensitizer development began in the 1970s and early 1980s. Second generation porphyrin
photosensitizers,
itizers, such as BPD, are porphyrin derivatives or synthetics. Another class of
photosensitizers are chlorin based, such as the HPPH used in the Phase I UPHS HPPH study
3

presented in this work. Each family of photosensitizers has its advantages and disadvantages,
depending on the type of tissue they are intended to treat. Photosensitizer development is
ongoing, striving to find a drug that meets the requirements of an ideal photosensitizer.
BPD is a second generation, porphryin-based photosensitizer. Its activation wavelength
is 690 nm, allowing for greater light penetration depth than many first generation
photosensitizers, whose activation wavelength was lower in the spectrum. It has a relatively
short period of light sensitivity (4-5 days), allowing patients to recover from acute
photosensitivity. A study of BPD as treatment for peritoneal carcinomatosis in canines was
conducted at UPHS. This study evaluated 15 canines with varying photosensitizer dose as well as
varying light fluence. The work presented here focuses on the spectroscopic methods used
during this study; obtaining optical properties, hemoglobin levels, oxygenation and
photosensitizer concentration of the canine intraperitoneal cavity.
The second photosensitizer we consider, HPPH, is a chlorin-based photosensitizer that
has an absorption peak at 665 nm. It has been used to treat head and neck, esophageal, and
lung cancers[37]. Currently, there is a Phase I study being conducted at UPHS and Roswell Park
Cancer Institute, treating patients with malignant pleural mesothelioma (MPM) using HPPH. This
thesis uses measurements of optical properties, fluence, and source position data from this
ongoing study.

1.1.2 PDT and optical properties
PDT efficacy is dependent on several factors. Drug uptake, light distribution in tissue,
and the geometry of the treatment region all affect the amount of cell damage that occurs. Light
distribution in tissue, depends in part on the absorption coefficient (µa) and the reduced
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scattering coefficient (µs’), of the tissue being treated. The absorption coefficient is defined as
the probability of photon absorption per unit distance and is measured in cm-1. The scattering
coefficient, µs, is the probability of photon scattering per unit distance in cm-1. The reduced
scattering coefficient then is defined by µs’=µs(1-g) where g is the mean cosine of the phase
function. By measuring these optical properties we are able to better determine what incident
light irradiance is needed for optimum treatment using the appropriate fluence model. The
geometry of the treatment region affects light distribution as well. Current protocol assumes all
treatment regions are planar and semi-infinite. PDT in cavity geometry, however, experiences an
increase in fluence caused by light reflecting off the cavity walls. By obtaining knowledge of in
ivo optical properties and correctly modeling the fluence in the treatment region, more uniform
light fluence can be achieved.

1.2 Malignant Pleural Mesothelioma
1.2.1 A brief introduction to lung cancers
Pleural cancers, including malignant pleural mesothelioma (MPM), non-small cell lung
cancer, and early small cell lung cancer, are historically difficult to treat and offer a prognosis of
6 to 15 months[38]. Primary pleural cancers are rare, with mesothelioma being the most
common. The source of malignant mesothelioma lies in the lining cells of the pleura and
peritoneal cavities[39]. Naturally occurring MPM is rare but exposure to asbestos, which was
used heavily in construction post World War II, increase the risk to developing MPM. Asbestos
use was largely abandoned in the Western World during the 1980s, but the long latency of MPM
(15 to 60 years)[39] means the instances of MPM continue to rise, particularly among men.
The difficulty in treating MPM lies in the ability of the treatment team to eradicate all
cancerous cells from the pleural cavity, as MPM often demonstrates widespread local
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disease[34, 40]. There is no standard treatment for pleural cancers [38, 41] though treatment
often begins with a surgical resection of the lung, parietal pleura, and the ipsilateral diaphragm
and pericardium [38]. While this procedure is vital in removing the bulk of the cancerous tissue,
it is impossible to remove this tissue without leaving behind a quantity of cancer cells in the
thoracic cavity [41]. Consequently, several different treatment modalities are being investigated
which combine surgical debulking with a follow-up treatment to kill off remaining cancer cells.
These modalities include chemotherapy, radiation therapy, and PDT. Chemotherapy, both
systematic and intrapleural, has not shown to eradicate cancer cells significantly, and radiation
therapy is limited in its application because of the need to spare nearby vital organs such as the
liver and remaining lung[38].

1.2.2 PDT as a treatment modality for MPM
PDT, by consequence of its limited light penetration into the tissue, is able to spare these vital
organs and sterilize remaining cancer cells. It offers a promising treatment option to pleural
cancer patients, particularly when coupled with the traditional methods of cancer treatment as
it does not present additional toxicities to affect the original treatment plan [41]. In 1996, a
Phase III trial was completed using the photosensitizer Photofrin to treat MPM[39]. The study
found that for surgeries where complete macroscopic resection was performed in conjunction
with PDT, the mean survival time was approximately 36 months, whereas in patients where
incomplete resection and PDT were performed the mean survival time was about 12 months.
With the development of second-generation photosensitizers and complete resection, PDT
applied to MPM offers a strong treatment method. The work presented here utilizes data
collected during the ongoing Phase I HPPH study, using mediated PDT to treat MPM. In
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particular, observations of optical properties and drug concentration are considered during
treatment.

1.3 Infrared Navigation System for Treatment
In
n this work, we present the development of a novel method to guide the PDT
treatment in order to achieve more uniform distribution of light fluence. Within the thoracic
cavity, the light delivery is continuously administered by a moving point source applied
applie by the
clinician.. We introduce a real
real-time
time infrared (IR) tracking camera to track the movement of the
light source. The same tracking device is also used to determine the surface contour of the
treatment area at the beginning of PDT treatment (see Figure 1.2).. It is at this point in the PDT
treatment where real-time
time dosimetry guidance becomes most critical. As the clinician applies
the light source, the knowledge of how well each particular area of the thoracic cavity is
irradiated has the potential to make the entire treatment process more effective and efficient.
The light source position data gathered by this system is then applied to the fluence model we
developed for a cavity geometry and is displayed on screen as a fluence map, to be used for the
clinician’s
’s guidance in applying the light source (see Figure 1.3).

Figure 11.2: Contour of torso shaped phantom with IR tracking data.
A contour is first taken of the perimeter of the phantom. Position data of the moving light sources (denoted by the
red circles) is gathered via the IR tracking system
system[42].
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Figure 1.3: Calculated light fluence using IR tracking data
Calculated light fluence using IR tracking data in a human torso-shaped phantom. The black x marks the location of
the isotropic detector, monitoring the fluence as current standard protocol dictates.[42]

1.4 Light Propagation and PDT
In PDT, the degree of cancerous cell death is dependent, in part, on how much light is able
to reach the targeted tissue. Light transport in biological matter is governed primarily by the
scattering and absorption of photons. These properties are characterized by the absorption
coefficient, µa and the reduced scattering coefficient, µs’.

1.4.1 Radiative transport model
This light propagation is described by a series of equations and boundary conditions known
as diffusion theory of light transport. The radiative transport equation (RTE), which will be
further discussed in section 2.1, can be solved using several different approximations. We focus
on the diffusion approximation as a solution to the RTE. The diffusion approximation first
assumes the number of photon scattering events is much greater than the number of photon
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absorption events (µs’>>µa). This is a reasonable assumption in most biological tissues in the
near infrared range (NIR) (see Section 2.8). A full treatment of the diffusion approximation is
discussed in Section 2.2. The diffusion approximation solution is dependent on the optical
properties of the tissue as well as the geometry of the treatment area.

1.4.2 Monte Carlo Simulations
Where the diffusion approximations fails, namely when µs’ is not much greater than µa or
where the change in current density is greater than one mean free path, or the asymmetric light
scattering is important, other methods can be applied to solve for the light distribution in the
tissue. We use Monte Carlo (MC) simulations (Section 3.4-3.7), a common method of fluence
modeling[43, 44] . MC simulations are based on the random walks of photons traveling through
a medium.
In these simulations we control the geometry, number of photons, and optical properties
of the system. The weight of the photon changes as each photon progresses via a uniformly
distributed random number generator after each scattering and absorption interaction. By
tracking the photons throughout the simulation we determine the total fluence, direct light
fluence, and scattered light fluence in the tissue. The results of the MC simulation are then
compared to the fluence calculated by the diffusion approximation solution or empirical
solution. We consider several different boundary conditions, tissue optical properties, the
properties of the medium inside the cavity, attenuation, and geometries to simulate treatment
conditions during PDT.
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1.5 Light Fluence Distribution and PDT Dosimetry
1.5.1 PDT dosimetry
PDT dosimetry, the measurement of photodynamic effect in tissue, is dependent not
only on the light distribution in the target tissue but also on the oxygenation of the tissue and
drug uptake of the target tissue[35, 45-48]. The current treatment protocol for both the BPD
canine study and the Phase I HPPH study, however, specifies only the total incident light fluence
and amount of photosensitizer administered[23, 32, 49] and does not account for the effects of
overall drug uptake and oxygenation unique to each patient and each tissue type, nor does this
protocol account for how the fluence changes in the tissue, versus fluence measured at the
surface of the tissue. Currently there are two methods used in these studies to perform PDT
dosimetry: a detector sutured into the tissue to measure fluence directly and a probe placed at
the surface of the tissue to measure optical properties and/or tissue oxygenation and drug
uptake and use these measurements to calculate fluence using an appropriate mathematical
model post treatment[45]. Of course, it is optimal to minimize the trauma experienced by the
tissue, making the noninvasive measurement of fluence more desirable for clinical applications.
But this method needs to be developed such that it provides light dose in real-time, specified by
the unique characteristics of the patient.

1.5.2 Fluence based Dosimetry
The fluence at some depth in tissue is modeled by several methods. The foremost
method, the diffusion approximation (see Section 2.2), is applied to fluence calculations often
and is a function of µa and µs’ and position. The diffusion approximation is not accurate near the
tissue boundary; a distance of 1 mm or greater from the boundary is where this approximation
holds. Other solutions are available to us, but are still dependent on µa and µs’. Section 2.6 will
go into further detail about methods used to determine these optical properties, but several
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assumptions are made to model fluence. First, while biological tissues are known to be
inhomogeneous, we assume them to be homogeneous in our models. Second, ex vivo
measurements of µa and µs’ are not necessarily equivalent to in vivo measurements of the same
tissue. It is important, therefore, to obtain characteristic ranges of optical properties in vivo for
fluence calculations. The P3 approximation is advantageous to use when the diffusion
approximation does not hold, eg. measurements close to the light source or where absorption is
high. By measuring the optical properties using spectroscopic methods we can estimate how
much light reaches tissues at certain depths and inform overall PDT dose.

Figure 1.4: An Illustration of PDT Cytoxic effect
The photosensitizer (PS) absorbs light and an electron moves to the first short-lived excited singlet state. This is
followed by intersystem crossing, in which the excited electron changes its spin and produces a longer-lived triplet
state. The PS triplet transfers energy to ground-state triplet oxygen, which produces reactive singlet oxygen
1
1
( O2). O2 can directly kill tumor cells by the induction of necrosis and/or apoptosis, can cause destruction of tumor
vasculature and produces an acute inflammatory response[50].

1.5.3 Oxygenation and PDT
The oxygenation levels of tissues are also an important factor in PDT dosimetry[23, 35,
51, 52]. The relationship between the PDT cytotoxic effect and singlet oxygen, 1O2, is complex.
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The photosensitizer begins in its ground state in a spectroscopic singlet, S0. When light is
absorbed, the molecules of photosensitizer are excited to their first singlet state, S1. In the
process of de-excitation, it transitions to the triplet state T1 and then transfers energy to a 3O2
molecule. This creates an extra 1O2 molecule as the photosensitizer returns to its ground state.
This process occurs many times, creating many 1O2. It is the interaction of the 1O2 with cellar
targets that induce the cytotoxic effect (see Figure 1.4). Clearly, PDT requires the presence of
oxygen to cause cell damage. If the treatment light intensity is too high, it may cause the tissue
to become hypoxic, reducing the oxygen available to PDT. Monitoring the oxygenation of tissues
during treatment helps to inform overall treatment outcome. Oxygenation in this work is
monitored using spectroscopic methods in vivo (see Section 3.3). Blood carries oxygen to
tissues, thus tissues with a higher blood supply, such as the liver, may be more susceptible to
PDT than tissues without a rich blood supply. Shielding sensitive organs during treatment
becomes important in the overall administration of PDT.

1.5.4 Photosensitizer uptake and dosimetry
Finally, the drug uptake, unique to each patient and each tissue type, is another
important factor in calculating accurate PDT dose. Because µa and µs’ are highly heterogeneous
between different tissues types and between patients, the amount of drug absorbed can vary
significantly. Photosensitizers used in PDT have a characteristic fluorescence signal[45] that can
be observed during treatment. Photobleaching, which can occur during treatment, is defined as
the destruction of fluorophores in the target tissue induced by irradiation. This destruction is
mediated predominately by 1O2 [35, 53, 54] for type II photosensitizers, destroying
photosensitizer molecules. Spectroscopic fluorescence measurements (see Section 2.7) of a
tissue before illumination will indicate the presence of the photosensitizer. Measurements
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made during and after illumination may show a decrease in the amplitude of the fluorescent
signal. By monitoring this signal, photobleaching may be observed and indicates the cytoxic
effect has occurred. Many groups are monitoring the fluorescent signal of the photosensitizer in
studies[23, 51, 52, 55, 56], and several are using this method in clinic[57, 58].

1.6 Spectroscopy
1.6.1 Diffuse reflectance spectroscopy
Diffuse reflectance is the light reflected at many different angles off a surface, and the
detection of the reflected light can provide information about the light distribution of the
medium being studied. Diffuse reflectance spectroscopy is used here to determine the in vivo
optical properties, [Hb]tot, and oxygenation levels. Several different methods of reflectance
spectroscopy have been developed, ranging from time-domain spectroscopy[17, 59, 60],
frequency-domain spectroscopy[61-65], to continuous wave (CW) spatially-resolved
spectroscopy. Using CW spatially-resolved spectroscopy, we determine the absorption and
reduced scattering coefficients of tissues by fitting spectra with an algorithm[66], to be
discussed in further detail in Section 3.3. Typical absorption and reduced scattering spectra of
human tissue in vivo are displayed in Figure 1.5
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(a)

(b)
Figure 1.5: Absorption (a) and reduced scattering (b) spectra
of human breast tissue in vivo measured by Cubeddu et al. [67]

The oxygenation of the tissue, important for determining the amount of expected cell death,
can also be determined from fitting CW reflectance spectra[68], determining the amount
oxygenated hemoglobin [HbO2] and de-oxygenated hemoglobin [Hb] present in the tissue. The
reflectance measurements performed for this work determine these properties for a wide
variety of organ tissues in vivo in canines and humans, helping to further inform our fluence
model.
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1.6.2 Fluorescence spectroscopy
The photosensitizers administered to the patient each have a characteristic fluorescence
spectrum that can be observed via light detectors during surgeries. When some photosensitizers
are exposed to its activation wavelength light for an extended period of time, photobleaching
can occur and is observable by diffuse fluorescence spectroscopy. Observing photobleaching is
one method of monitoring the PDT effect of irradiation of the treatment area[51]. By monitoring
the shape of the photosensitizer’s spectrum during treatment, we can determine the
photodynamic dose[35] implicitly (observe a typical fluorescence spectrum in Figure 1.6).

Figure 1.6: Measured fluorescence of HPPH over time
Measured tissue in vivo on a nude mouse. Note the amplitude of pre-PDT fluorescence (blue) to
post-PDT fluorescence (red)

The measurements presented in this work were taken before and after treatment. Using the
basis spectra of the fluorescence of BPD and HPPH, determined via a series of murine studies,
we fit our fluorescence measurements made in vivo to determine drug concentration before
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and after treatment. This is a useful tool is determining both drug uptake by a variety of tissues
and also received light fluence.

1.7 Statement of Purpose
PDT treatment planning, particularly light fluence (“light dose” in clinic) calculation, has
potential to be improved, and, in turn, improving PDT treatment outcome. When a cavity of
arbitrary geometry, such as those observed in the Phase I HPPH study at UPHS, is illuminated,
the overall fluence increases due to multiple scattered photons in what is known at the
Integrating Sphere Effect (ISE)[5]. Current pleural PDT treatment protocol for treatment of the
thoracic cavity at the UPHS monitors fluence discretely in the thoracic cavity of the patient. Light
is delivered to the detectors to reach the predetermined prescribed total fluence. This protocol
measures the light at discrete locations, and does not give the total fluence received by the
whole cavity. Valuable information from in vivo spectroscopy measurements can provide total
hemoglobin concentration and oxygenation of the treatment tissue in addition to optical
properties.
Light dose calculation for pleural PDT can be improved by considering these two factors of
geometry and in vivo spectroscopy data that has not previously been studied in the thoracic
cavity and require further exploration.
To more accurately model the light dose in a cavity, we expanded the work presented by
Willem Star[69] in regards to the ISE in a spherical cavity. A series of Monte Carlo (MC)
simulations were run for semi-infinite planar, spherical, and ellipsoidal geometries for a range of
optical properties. The results of these simulations are then compared to the theory as well as
numerical solutions for fluence both in the cavity itself and at the cavity-tissue boundary. A
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verification of these MC simulations offers a new method of determining the required light dose
that is specialized to each treatment volume, shape and optical characteristics. The analytical
theory Star presents, which will be derived in section 2.4, is dependent on the in vivo optical
properties (µa and µs’) of the tissues being treated. The optical properties are highly variable
between tissue type and between patients[70]. Here we use spectroscopy methods to
determine the in vivo optical properties for the tissues present in the interperitoneal region in
canines and in the thoracic cavity in humans.
This thesis, by developing a fluence model for cavity geometries and determining the in
vivo optical properties obtained during treatment, presents the tools to improve prescribed light
fluence and specialize light dose to each patient in the future. We aim, with this work, to
provide the building blocks essential to improving pleural PDT efficacy by more accurately
calculating the required light dose using a model that accounts for the ISE and uses optical
properties measured in vivo, obtained via spectroscopic measurements. With improved PDT
treatment efficacy, the treatment plan and prognosis for patients with MPM has the potential to
improve as well.

1.8 Outline
The work presented here is organized in the following manner: Chapter 2 discusses in
greater detail the diffusion approximation as applied to light transport in biological tissue. It also
provides the theory and background information for the spectroscopic methods used to analyze
data for this thesis. Chapter 3 addresses the instrumentation and fitting algorithms used to
obtain the optical properties, oxygenation levels, and drug concentration from diffuse
reflectance and fluorescence measurements. The data collected from the BPD canine study and
the HPPH Phase I clinical trial is also presented in Chapter 3. Chapter 4 expands further on
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fluence modeling and MC simulations used to calculate the fluence in different geometries.
Chapter 5 discusses the IR navigation system that is in development, which will utilize both the
determined optical properties and the fluence model presented here. It is a novel tool, using the
modeling developed here in conjunction with an infrared (IR) camera as a fluence tracking
system for the clinician’s use during pleural PDT. Finally, Chapter 6 concludes this work by
summarizing our findings and discussing future applications of the work completed here.
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Chapter 2

Theory and Background
2.1 Introduction
In order to model light distribution in PDT and also to determine experimentally the properties
of the tissues we treat, we must provide a rigorous theoretical description of light propagation
in turbid media. This chapter provides the necessary mathematical framework. Section 2.2
describes the diffusion approximation to the radiative transfer equation (RTE) using simple
boundary conditions and geometries. Section 2.3 goes further to describe the solution to the
RTE when considering a semi-infinite, homogeneous, planar geometry for different
approximations to the RTE. Section 2.4 focuses on the work of Star[69] and van Staveren[5] to
describe the solution to the RTE in a spherical cavity geometry. Section 2.5 presents the theory
behind determining the optical properties using diffuse reflectance measurements. Section 2.6
describes the theory behind the fluorescence measurements that are used for determining PDT
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drug concentration. Finally, Section 2.8 presents a review of in vivo optical properties
determined in human subjects from the literature.

2.2 Photon Diffusion Approximation
Radiative transport theory provides a mathematical model for the propagation of
neutral particles through scattering and absorbing media. Ignoring the effects of polarization,
phase, and inelastic scattering events, the radiance, L(r,ŝ’), defined as the power per unit area
per unit solid angle in direction ŝ at position r, is described by the time independent Boltzmann
equation [71]:
 · , ̂ ̂
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 , ̂  ̂ , ̂  Ω  , ̂ ,


( 2.1 )

where µt=µa+µs, the absorption coefficient (µa) is the probability of absorption per unit distance
and the scattering coefficient (µs) is the probability of scattering per unit distance. S(r,ŝ)
represents the source term. The term f(ŝ,ŝ’) is the scaPering phase funcQon, describing the
probability that a photon incident in direcQon ŝ’ will be scaPered into direcQon ŝ. Equation ( 2.1 )
describes the gradient in radiance distribution, where L(r,ŝ) is decreased by absorption and
photons that are scattered away from direction ŝ (first term on the right hand side of the
equation) and is increased by photons scattered into ŝ and by the light source, S(r,ŝ) (remaining
terms). The source term S(r,ŝ) is represented in a variety of ways, depending the light source
used. For planar geometries, the light can be a wide beam with collimated incidence (referred to
as a pencil beam or a wide beam with diffuse incidence. For spherical geometries, a point source
is most commonly used in models. For cylindrical geometries, a long, linear light source is used.
Each of these light sources are represented via appropriate and unique mathematical
expressions. The two light sources used in this work are a pencil beam, used in our MC
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simulations and later convolved to an isotropic point source for cavity geometries, and a simple
isotropic point source.
The scattering phase function f(ŝ,ŝ’) is assumed to depend only the deflection angle θ
between s and s’. f(ŝ,ŝ’) becomes a complicated function in turbid biological media, due to the
high particle density and inhomogeneity of tissue. An accepted approximation for f(ŝ,ŝ’) is the
Henyey-Greenstein phase function[72]:
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where the general expression for g is the scattering anisotropy, expressed as:

$

 ,
) ̂  Ω.


( 2.3 )

The quantity g is equal to the average of the scattering cosine θ. The scattering anisotropy
ranges from -1, which indicates backward scattering, to 1, which indicates forward scattering. If
g=0 then the scattering has no net preference for forward or backward scattering. In this work,
we assume g≈0.7-0.9, accounting for the anisotropic scattering observed in tissue.
Equation ( 2.1 ) is analytically solvable in the instance of one-dimensional, idealized
geometries, but these idealized situations are not applicable to calculating the light distribution
in real-life experimental situations[71]. While several numerical methods have been employed
to solve eqn. ( 2.1 ) for a particular geometry (eg. Kubelka-Munk[73] and Adding-Doubling[74]
methods), the spherical harmonic approximation provides a series of approximations to simplify
the solution, which expands the radiance and sources terms as a series of spherical harmonics
and the scattering phase function as a series of Legendre polynomials:
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The series of equation ( 2.4a ) are truncated at the Nth term (referred as the Pn approximation)
and are then substituted into eqn. ( 2.1 ). For the diffusion approximation, N=1, with l=0,1, eqn. (
2.4a ) becomes:
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The radiance is composed of the fluence rate, φ(r), and the radiant flux, F(r). The fluence rate is
defined as the power incident on an infinitesimal sphere divided by the cross-sectional area of
the sphere (eqn. ( 2.6 )), and the radiant flux is defined as the power transferred per unit area
(eqn. ( 2.7 )).
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The divergence of the flux is found by substituting eqn. ( 2.5a ) into eqn. ( 2.1 ) and integrating
over all solid angles eqn.( 2.8 ),
 · >
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Using eqn.( 2.8 ), we can determine the gradient of the fluence by multiplying by ŝ and once
again integrating over all solid angles:
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The quantity S1(r) is zero everywhere when only isotropic sources are considered. The reduced
scattering coefficient, µs’=(1-g)µs. Combining eqns. ( 2.8 ) and ( 2.9 ), we arrive at the timeindependent diffusion equation for an isotropic source:
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Here, D=1/3(µa+µs’), is the diffusion constant. A simplified form of eqn. ( 2.1 ), eqn. ( 2.10 )allows
us to solve for φ given a specified set of boundary conditions and geometry.

2.3 Semi-Infinite Approximations for fluence and reflectance
2.3.1 Analytic Approximation for a wide, diffuse light source
Assuming the tissue to be a semi-infinite plane is a common practice for determining
the light distribution from a wide, diffuse beam. In order to determine φ(r), the Green’s function
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is found as a solution to eqn.( 2.10 ) at some tissue depth z0. We consider first the case where
the refractive indices of the non-scattering and tissue match, where there is no photon current
back into the tissue. This boundary condition is expressed as[75]:

.  2BCD · .

0

( 2.11 )

where n̂ is a unit normal vector directed into the tissue. To solve eqn. ( 2.10 ) for a semi-infinite
plane we use a photon dipole source and an extrapolated boundary condition. Equation ( 2.11 )
is fulfilled by setting the fluence equal to zero at a distance of 2D above the planar surface (see
Fig. 2). For the case of refractive index mismatch between the non-scattering medium and the
tissue, the boundary condition is[76]:
<  2FBCD · .

0,
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where A is a constant dependent on the Fresnel reflection coefficients and indices of refractions.
The analytic expression for A is given by [66]. :
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R0 depends on the ratio of the indices of refraction, nrel= nair/ntissue. R0=[(nrel-1)/(nrel+1)]2 [66]. For
the case of matching indices of refraction, A=1. An empirical model was developed by
Groenuis[77] for A:
A

1  N
,
1 N

where rd is determined empirically by Egan and Hilgeman[78]:
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( 2.14 )

( 2.15 )

Unless stated otherwise,
e, eqn.
eqn.( 2.14 ) and eqn.( 2.15 ) will be used hereafter for the values of A
and rd. For mismatched indices of refra
refraction the boundary condition, eqn. ( 2.12
12 ), is satisfied if
the fluence is set to zero at a extrapolated boundary at zb=2AD [79]. The distance zb is referred
as the extrapolated
xtrapolated boundary (see Figure 2.1) To implement the photon dipole model, an
“image source” is placed distance z0+2zb above the tissue surface for photon att a distance z0
(where z0 is the depth of the photon in the tissue).

Figure 2.1:: Configuration for extrapolated boundary conditions for an air-water
water interface.
I

The problem is then treated as though we are solving for the fluence for two point sources (real
and image) in an infinite medium. The Green’s function for an isotropic point at a position (0,z0)
in an infinite medium is given as:
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where r1=[(z-z0)2+ρ2]1/2, with ρ the radial distance from the point source. The total fluence for a
semi-infinite planar medium with mismatched indices of refraction is:
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where r2=[(z+z0+2zb)2+ρ2]1/2. Equation ( 2.17 ) is analytic diffusion approximation for fluence in a
semi-infinite medium. The corresponding expression for reflectance will be derived in Section
2.6.2.

2.3.2 P3 Approximation
Following the work of Hull and Foster[68], the P3 approximation to eqn. ( 2.1 ) is
developed by expanding the spherical harmonics Ylm for the angular quantities in eqns. ( 2.4a )
and ( 2.4a ) to l=3 to solve eqn. ( 2.1 ). This expansion gives a set of 16 first order differential
equations. This set can be further simplified to for a homogeneous medium with an isotropic
point source. By symmetry this problem reduces to one dimension, resulting in only four
differential equations that can be solved directly. This expansion, for a slab of infinite length and
finite width, is a detailed derivation. For full derivation please see A.1 . From the final expansion,
for a homogenous semi-infinite medium with an isotropic light source, the fluence is given as:
Z6

[Q 3\

]^

 BQ 3\

_^

( 2.18 )

where the C, D, ν-, and ν+ are defined in A.1 . The complicated expression of eqn. ( 2.20 ) was
later verified [80] via MC simulations and phantom measurements and was found to be more
accurate in calculating fluence than the analytic diffusion approximation approach.
26

For this treatment, the reflectance is given by determining how much light is
transmitted across the boundary:
GN` O; P6



ΩfSg

bcU` dcos34 ̂ · CD e, ̂ ; P6 CD · ̂ Ω,

( 2.19 )

where Tfres is the Fresnel transmission factor, cos-1(s x n) describes the angle of incidence on the
boundary, and Ωdet is the solid angle subtended by the detector. Equation ( 2.19 ) is the general
expression for reflectance. When the term , ̂ ; P6 is expanded in spherical harmonics for l=1,
this is the diffusion approximation. When this term is expanded to l=3, this becomes the P3
approximation. The P3 approximation overcomes the limitations of the diffusion theory
approach, determining optical properties accurately where there is relatively high absorption
and at short s-d separations. Yet the P3 approximation also has its limitations and loses accuracy
at small field sizes (<2 mm) [81].

2.4 Spherical Cavity Approximation
In clinical applications of intercavity PDT, such as the bladder or the thoracic cavity, it is useful to
model light fluence in a cavity. The diffusion approximation can be applied to solve for the
fluence by using the appropriate boundary conditions and accounting for light backscattered
into a spherical cavity. To solve for the fluence in a spherical cavity we first consider the
relationships between the net energy flux, radiance, and fluence. Recall eqn. ( 2.7 ) expresses
the net energy flux in terms of radiance L(r,ŝ). Suppose the photon density distribution, N(r,ŝ)I, is
slightly anisotropic by a small shift ε (ε<<1). The entire photon distribution density can then be
expressed as:

i,
jj ̂

i6  k
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1  l ̂ · mD
n
4"

( 2.20 )

where û is a unit vector pointing in the direction of interest. Using eqn. ( 2.20 ), the radiance,
similar to eqn. ( 2.5a ) then becomes:
, ̂

6  d1  l ̂ · mDe,

( 2.21 )

Note that eqn.( 2.21 ) differs from eqn.( 2.5a ) in that here r represents the radial direction in a
spherical coordinate system.
Combining eqn. ( 2.7 ) for the net energy flux and eqn. ( 2.21 )a new expression for radiance in
terms of F(r) is determined:
, ̂
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3
> · ̂ ,
4"

( 2.22 )

where 4πL0(r)=φ(r). The flux F(r) has direction, however, and is broken up into two expressions:
flux in positive direction, Fn+(r), and flux in the negative direction, Fn-(r):
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( 2.23a)

( 2.23b )

Simplifying eqn. ( 2.23a), we find new expressions for Fn+(r) and Fn-(r) in terms of F(r):
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( 2.24a )
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( 2.24b )

Adding eqns. ( 2.23a) and ( 2.23a) together relates the total scattered fluence to the positive and
negative fluxes:
2d>op   >o3  e.

. 

( 2.25 )

Equation ( 2.25 ) is an important result of diffusion theory and will be used to determine the
fluence in a spherical cavity and its surrounding medium.
Following the derivation presented by Star [73], assume we have a spherical cavity of
inner radius rc and whose outer radius approaches infinity. Because the cavity is radially
symmetric, the problem reduces to one dimension. Further assuming we have an isotropic point
source with power P such that S(r)=P/4πr2, and applying eqn. ( 2.25 ), eqns. ( 2.8 ) and ( 2.9 )
become:
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( 2.26a )

( 2.26b )

Equation ( 2.26a ) is then solved for the total fluence rate by applying the boundary condition of
continuity at the cavity wall, Fr+(rc)=Fr-(rc). The total fluence rate in the medium surrounding the
cavity is determined to be:
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Section 4.3 will expand upon eqn. ( 2.27 ) to determine the fluence rate within the cavity and to
compare the diffusion approximation solution to integrating sphere theory. Accurate modeling
of fluence in a cavity is important when considering treatment of the bladder, the thoracic
cavity, and other treatment sites where the backscattered photons become important in
determining PDT dosimetry, increasing the overall fluence.

2.5 Diffuse Reflectance
2.5.1 Introduction to models used to determine diffuse reflectance
Several different techniques have been implemented to determine optical properties,
hemoglobin concentration, [Hb]tot, and tissue oxygenation (StO2) in vivo using diffuse reflectance
measurements. Time-resolved spectroscopy and frequency resolved spectroscopy of diffuse
reflectance are two alternative methods but will not be explored further here, as they are
beyond the scope of this thesis. Continuous wave spatially resolved spectroscopy is the
experimental method applied here to determine the needed optical properties, [Hb]tot, and
StO2. Knowledge of these properties helps to inform modeling of light distribution in tissue. This
method records reflectance remitted from the target tissue at several different distances from
the light source. The measured spectra are then fitted with the appropriate model to determine
µa and µs’, [Hb]tot, and StO2 (these fitting algorithms are discussed in detail in Chapter 3).

2.5.2 Extrapolated Boundary Conditions
Farrell et al. [66] present a radially resolved, steady state model based on diffusion
theory (see Section 2.2). Several assumptions are made. First, we assume the absorption is
much less than the scattering in the target tissue (µa << µs’). Second, we assume measurements
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of reflectance are made at least one free mean path from the light source. The first assumption
generally holds in the therapeutic window (650-950 nm) and for the studies presented here this
assumption is reasonable. Section 2.3.1 presents the framework for determining the reflectance
in relation to fluence. Equations ( 2.11 ) and ( 2.12 ) are the boundary conditions that are
applied to eqn.( 2.10 ) to arrive at the following relationship:
B.xO, P |^26 ,

GO, P

( 2.28 )

where ρ represents the radial distance from the z-axis. Recalling Eqn.( 2.17 ), the Green’s
function for an isotropic point source, we solve for R(ρ,z):
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Recalling that r1 and r2 are functions of z,z0,zb, and ρ Eqn.( 2.31 ) becomes[60]:
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To determine the total diffuse reflectance, we integrate eqn.( 2.30 ), weighted by the source
strength of all interaction sites along the z-axis (see Figure 2.1), over the entire target tissue
surface:
GN P6
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( 2.31 )

( 2.32 )

Eqn.( 2.32 ) is further simplified by the following relationships:
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( 2.34 )

and assuming the diffusion approximation, the total diffuse reflectance becomes[66]:
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Equation ( 2.35 ) is an important expression. By fitting measured reflectance data with this
expression we are able to determine µa and µs’ unique to each tissue measured so essential to
light fluence modeling. Keinle et al. discuss the three common boundary conditions: zero
boundary condition (ZBC), extrapolated boundary condition (EBC), and partial current boundary
condition[60], and conclude the EBC treatment of the reflectance-fluence relationship
determines optical properties within 10-15% of the actual values. This makes the EBC treatment
the most effective method of determining optical properties, total hemoglobin concentration,
and oxygenation from diffuse reflectance measurements when using a diffusion theory[66, 79,
82].

2.5.3 Diffusion theory-P3 hybrid model
While diffusion theory is commonly applied to determine µa and µs’ and [Hb]tot and StO2
from reflectance measurements, this method has limitations. Diffusion theory is not applicable
for tissues with high absorption nor at source-detector (s-d) distances less than one free mean
path. The expression for reflectance (eqn. ( 2.19 )) derived using the P3 approximation
overcomes the limitations of the diffusion theory approach, determining optical properties more
accurately where there is relatively high absorption and at short s-d separations. Using the
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hybrid P3 model[68] allows us to determine these properties with even greater accuracy near
the boundary.

2.6 Fluorescence
Fluorescence measurements in vivo are used to determine photosensitizer
concentration. Fluorescent light is emitted by fluorophores naturally present in tissue and also
by photosensitizers used in PDT. The naturally occurring fluorescence is referred as
autofluorescence and, as discussed in Chapter 3.2.3, is accounted for when determining drug
concentration. Fluorophores, molecules that emit light when excited by light of a particular
wavelength, each have a unique fluorescence spectrum that allows the determination of optical
properties and drug concentration. The fluorescence signal is measured using a variety of
methods. In this work, a fiber optic probe is used. One fiber emits the excitation light while a
second fiber detects the resulting fluorescence emission.
Although we do not use our fluorescence measurements to determine optical
properties in this work, it is worth discussing briefly. The fluorescence signal is generated by a
collection of fluorophores present in the target tissue. The fluorescent emission is isotropic and
its source function is described by[83]:
6
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( 2.36 )

where σf and μaf are the fluorescence quantum yield and excitation-wavelength absorption
coefficient of the fluorophore, respectively, φx(r) is the fluence of excitation light, and the
wavelength ratio (λx/λm) accounts for the difference in photon energy between the excitation
and emission wavelengths. We assume the fluorophores are uniformly distributed throughout
the target tissue and also have uniform quantum yield. The detected fluorescence signal is then
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a function of the optical properties of the tissue, the fluence at the excitation wavelength, and
position.
Measured fluorescence data is also used to determine the photosensitizer
concentration in tissues in-vivo, which in turn is another method of implicit PDT dosimetry[35].
The fitting algorithm used to determine the drug concentration in tissues is discussed in detail in
3.3.2. Photosensitizers each have a unique fluorescence spectrum. By monitoring the spectrum
before and after illumination, we can determine the relative concentration of the
Photosensitizer in the measured tissues. Photobleaching, where fluorophores are destroyed
from exposure to 1O2, becomes important as it can serve as an indicator of how much tissue
damage occurs. We measure photobleaching as the loss of fluorescence emission during
treatment. The magnitude of photobleaching observed depends on the incident fluence rate,
the oxygenation of the target tissue, and the optical properties of the target tissue. Several
different models exist to describe the relationship between the fluorescence emission of a
photosensitizer and these factors [35, 53]. The fluorescence spectra measured may be distorted
by the absorption and scattering of the tissue[84]. A method for accounting for this distortion
using the corresponding reflectance data is discussed in 3.3.2.

2.7 Range of Optical Properties
The in vivo optical properties µa and µs’ vary greatly between tissue type and often
between tissue of the same type from different specimens. An overall range of µa and µs’,
however, can be found in the literature. The absorption coefficient, µa, is determined by the
presence of chromophores in the tissue. Chromophores are the light-absorbent components of
tissue. Each chromophore has its own unique absorption spectrum, and the concentration of
different chromophores create the overall absorption spectrum of a tissue. The dominant
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chromophores in tissues are hemoglobin (deoxyhemoglobin and oxyhemoglobin) and, in skin
melanin. Hemoglobin is a red-colored protein that carries oxygen from the lungs to the rest of
the body within red blood cells. It is the sum total of oxyhemoglobin (oxygen bound
hemoglobin) and deoxyhemoglobin. The absorption spectra of oxyhemoglobin and
deoxyhemoglobin differ (see Figure 1.1). Analysis of the measured absorption spectra of tissues
can reveal the oxygenation of the tissues, which is, as discussed in Section 2.5, an important
factor in PDT dosimetry. The brown-black pigment melanin is an important absorbing
chromophore in the skin. Melanin absorbs light between ~330 nm and 700 nm and is a
particularly strong scattering source in the ultraviolet part of the spectrum (see Figure 1.1). The
concentration of each absorber can be determined by analyzing the full spectrum of µa(λ) for a
particular tissue.
The reduced scattering coefficient µs’ is dependent on the presence of cells and cell
morphology. Light is scattered by cell nuclei at large incident angles, the cells themselves at
small incident angles, mitochondria, lysosomes, and Golgi apparatus. µs’ decreases
monotonically with increasing wavelength and is often modeled by Mie theory. In Mie theory,
scattering sources are treated as individual spheres that are distributed either monodispersely
or polydispersely and interact with a planar electromagnetic wave. The scattering is dependent
on the radii of the spheres and the index of refraction and can be shown to be mostly in the
forward direction. Mourant et al. [85-87] conducted several studies of scattering in biological
tissues and concluded that about 40% of scattering is caused by the cells nuclei and their substructures. Other organelles in the cell cytoplasm contribute greatly to scattering at large
incident angles.
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Table 2.1 lists the measurements of optical properties of in vivo (µa and µs’) human
tissue at room temperature (22o C) for treatment wavelengths commonly used for PDT; the
method used to obtain the optical properties is also listed. Figure 2.2 presents the spectra of
human tissues in vivo for µa and µs’ as a function of wavelength. The data was taken from the
literature for respective tissue and optical properties, and were fitted with a series of best-fit
lines (R2 > 90) using the software package STATATM. The data then compared to the resulting fit
to the best-fit line, and a 95% confidence interval was obtained from this comparison (denoted
by the gray band in Figure 2.2). For wavelengths λ> 690 nm where the absorption of hemoglobin
is no longer dominant, tissue optical properties will be affected strongly by the absorption of
photosensitizer. As a result, the spatial distribution and dynamic photobleaching of the
photosensitizer will affect the in vivo optical properties. For example, the peak observed at 740
nm in prostate tissue is caused by the presence of a photosensitizing drug, Motexafin Lutetium.
The result of this analysis is the overall trend in µa and µs’ as a function of wavelength for
particular human tissues in vivo observed in the available literature.
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(a)

(c)

(b)

(e)

(g)

(f)
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(g)

(i)

(h)

(j)
Figure 2.2:: Absorption and Scattering coefficients for human tissue in vivo

Absorption and Scattering coefficients of human tissue in vivo versus wavelength for breast (a
(a) [67,
[ 88-91], (b) [8993], b); skin (c) [18, 70, 94-96], (d)
d)[18, 70, 95, 96]; prostate (e) [11, 17, 20, 24], (f)[19, 20, 97, 98]]; small bowel (g)
[70],(h) [70]; and bone (i) [99], (j)
j) [99]. The grey shaded region is the range of µa and µs’ with a 95% confidence
interval based on review of the literature.
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Table 2.1: In vivo optical properties at commonly used treatment wavelengths for PDT
Tissue
Bladde
r

λ (nm)
532

µa (cm-1)
0.27-0.71

µs’ (cm-1)

Experimental Method

1.28-3.30

4

[100]

630

0.28-0.76

2.5-6.37

4

650

0.09-0.14

12.5-15.8

1

760

0.07-0.09

11.9-14.1

1

420

0.01-3.51

18.75-55.83

4

532

0.02-3.84

0.10-46.3

4

630

0.02-0.50

3.72-21.97

4

760

0.11-0.17

4.0-10.5

1, 2

780

0.078-0.089

8.42-9.16

2

660

0.037-0.110

11.4-13.5

1,4

760

0.031-0.10

8.3-12.0

1,4

900

0.096-0.29

3.33-5.86

1,4

530

0.60-0.86

28.0-32.1

4

690

0.070-0.10

14.7-17.3

2

895

0.068-0.102

12.4-13.1

2

Small

630

0.19-0.21

8.95-10.05

4

Large

630

0.12-0.18

10.11-10.42

4

Diaphr
agm
Heart

661

0.15-1.08

9.65-21.7

4

Bone

Brain

Breast

Tumor

References

[100]
[99]
[99]
[100]
[100]
[100-102]
[103, 104]
[105]
[67, 89-91, 93, 106]
[91, 93, 106-109]
[88, 91, 106, 110]
[92]
[94]
[94]

Bowel

630

0.03-1.55

17.56-75.06

661

0.12-0.18

5.22-90.80

4

Liver

630

1.15-1.56

21.6-30.4

4

Lung

630

0.16-1.36

1.07-83.81

4

661

0.49-0.88

21.14-22.52

4

630

0.13-0.33

13.0-21.9

4

3.41-17.02

4

5.24-22.68

4

630
650

Skin

0.05-1.0
0.14-0.61

[113]
[112]
[70, 111]
[113]
[112]
[70, 111]
[98, 114]

672

0.09-0.72

7.1-25.0

1,3

732

0.09-0.72

3.37-29.8

4

762

0.11-1.6

1.2-40.0

2

630

0.05-1.11

2.26-20.95

1,4

661

0.51-0.64

2.24-5.77

4

800

0.16-0.23

6.80-9.84

1

1. Time of flight absorption spectroscopy
3. CW Absorption Transmittance Spectrsocopy

[70, 111]
[112]

4

Pericar
dium
Prostat
e

[70, 111]

[19, 98, 115]
[17, 18, 98, 115]
[17, 24, 115]
[15, 17, 20, 21, 115]
[11, 70, 113, 116,
117]
[93, 112, 118]
[93, 95, 96]

2. Frequency Resolved Spectroscopy
4. CW Absorption Reflectance Spectroscopy
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Chapter 3

Spectroscopy
3.1 Introduction
Diffuse reflectance and fluorescence spectroscopy is a vital tool in optimizing PDT. The studies
presented here use a fiber optic probe that sequentially measures the reflectance spectra and
the fluorescence spectra of the tissue. As discussed in chapter two, reflectance measurements
are used to determine not only the in vivo optical properties of the tissue, but also, with a series
of fitting algorithms, the oxygenation saturation and blood concentration of the tissues.
Although these properties can change during treatment and are unique to each patient and
each tissue type, in vivo measurements provide an overall range of properties that one can
expect to observe in further studies. In vivo fluorescence measurements provide a method of
monitoring treatment beyond current standard protocol. The pre clinical canine BPD trial
presents in vivo reflectance and fluorescence data previously unavailable in the literature.
Working with the photosensitized BPD also provides an opportunity to further understand the
behavior and effects of this photosensitizer. The Phase I HPPH trial also provides in vivo
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reflectance and fluorescence data for the first time. An analysis of these two studies informs our
dosimetric model and may potentially improve PDT efficacy.

3.2 Instrumentation
Reflectance
ance and fluorescence measurements were made using a fiber optic probe that
was made in-house.
se. The probe, shown in Figure 3.1, is made of two source
e fibers and 9 detector
fibers.. One source fiber is illuminated by a tungsten lamp (Avalight, Avantes, Inc.) for reflectance
measurements. The source fiber is turned on while the nine detectors collect the reflected light
(see Figure 3.1).
). The second source fiber is illuminated by a low intensity laser (wavelength=403
nm). This is the excitation light for fluorescence measurements. Once reflectance data is
collected,, the white light source fiber is turned off and the 403 nm light source is turned on and
data is collected. All eleven fibers are bundled together, with fiber separations depicted in
Figure 3.2. The entire probe is encased by Black heatshrink over 8.5 mm (ID) Stayput Steel cable
(Armor Associates SP-8.5).

Figure 3.1: Spectroscopic Probe
Spectroscopic probe head (left) and trigger button (right). Light sources are on the far right of the probe head, with
detectors placed at increasing distance. The LED light on the probe handle indicates to clinician when the
measurement system is ready to be used.
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The data collection
ection process is triggered by a push button, which is controlled by the clinician. All
Al
collected light is coupled to a CCD based spectrograph (InSpectrum, Roper Scientific, Princeton,
NJ), recording a spectrum from each detector. Spectroscopic measurementss were obtained in
the following order by the CCD: diffuse reflectance (white light on), background (no source on),
and fluorescence (403 nm laser on). The cycling sequence was repeated six times for each
measurement and later averaged to reduce noise.

Figure 3.2: Source detector separations in cm
Source 1 is the white light source used for reflectance measurements, the second circle represents the 403 nm light
source used for fluorescence measurements.

The data collected by the spectrograph is stored and then processed before it is fit using
the algorithms described in section 3.3. Data is corrected for CCD offset and instrument
variation.. The CCD offset is corrected by subtraction of an averaged dark frame (the background
measurement collected). To correct for the instrument spectral response, measurements made
in an integrating sphere are used. The probe is placed at the center of an integrating sphere.
sphere The
use of an integrating sphere, which is coated in white reflecting paint, allows us to record in
variation in fiber throughput, light source variation, and the spectral response of the CCD.
Measured reflectance is divided by the spectrum obtained in the integrating sphere.
sphere The six
frames collected are averaged
raged together and normalized by the maximum of each spectrum and
then saved for further analysis.

3.3 Fitting Algorithms
Once the reflectance and fluorescence data is processed the following fitting algorithms are
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applied where appropriate. Radially (Section 3.3.1) and spectrally (Section 3.3.2) fitting of
diffuse reflectance measurement allow us to determine the optical properties and the
hemoglobin and oxygenation levels respectively. Spectrally resolved fitting of fluorescence data,
using the appropriate basis spectrum, determines the relative photosensitizer concentration.
The outputs of each fitting process provide valuable information for determining light fluence
distribution, as discussed further in Chapter 4.

3.3.1 Diffuse reflectance radially resolved fitting
As mentioned in section 2.3.2, Hull and Foster [68] developed an expression for
reflectance using the P3 approximation. Equation( 2.19 ) is used to fit the radial profile of
reflectance measurements to determine the optical properties of the measured tissue. Applying
the P3 approximation in this manner is advantageous over the diffusion approximation for
reflectance because it is valid at small source-detector separations, which allows for smaller
measuring instruments to be used in the clinic.
Nichols et al. [119] applied the solution for reflectance derived by Farrell et al. [66], a
diffusion approximation based solution, to fit the radial profile of reflectance measurements to
determine the optical properties of turbid media. For the work presented here, we apply the
same overall fitting technique, only using Hull and Foster’s P3 approximation for reflectance as
opposed to Farrell’s. We normalize the measure reflectance:
GN,oU0

GN O

GN

,

( 3.1 )

where Rd(ρnorm) is measured reflectance at a known distance ρnorm. In this way we consider only
the shape of measured spectrum, independent of intensity. A theoretical reflectance radial
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profile is fitted to the measured reflectance radial profile using a nonlinear optimization
algorithm, fminsearch, available in Matlab, to determine µa and µs’ via radial distance fitting.
The function fminsearch is an unconstrained nonlinear optimization algorithm based on
the work of Lagarias et al. [120]. It finds the minimum of a scalar function of several variables
given an initial estimate. In this instance, an initial estimate of µa and µs’ are given to generate
the theoretical radial profile. We assume eqn. ( 2.19 ) is continuously differentiable and run
fminsearch iteratively until the difference between the theoretical spectrum and measured
spectrum is minimized. The minimum reached is a local minimum only. If the initial values for µa
and µs’ differ drastically from the true µa and µs’ then another, local, minimum may be reached,
returning incorrect values for µa and µs’. We conducted a phantom study, with known optical
properties, to test how the initial values of µa and µs’ given to the fitting algorithm affect final
values of µa and µs’.
Four liquid phantoms were made using black India ink (for absorption), IntralipidTM (for
scattering), and water. The absorption coefficient of the India ink was determined using an
absorption spectrum spectrometer (Ocean Optics cuvette holder, TE-cooled CCD spectrograph)
from a series of measurements made using nine different concentrations of the same ink used in
the phantom measurements. Each of the four phantoms (see Table 3.1) was measured a total of
four times, with five frames per measurement, collected by the 9 detectors of the probe
described in section 3.2. Our purpose in making repeated measurements was to observe the
spread in resulting optical properties from a series of measurements on the same sample.
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Table 3.1: Tissue Phantom Optical Properties

µa (cm-1)
1.2
1.22
1
0.5

Phantom
A
B
C
D

µs’ (cm-1)
16.5
18.0
25
15

We tested how dependent the resulting optical properties from our fitting algorithm are on the
initial guess used in the algorithm. We do this by fitting the phantom data (of well-known optical
properties) repeatedly, using different initial guesses and comparing the output of the
algorithm. We present the results from Phantom A (μa=1.2 (cm-1) and μs’=16.5 (cm-1)) here, with
initial guesses listed in Table 3.2.
Table 3.2: Initial Guesses for Phantom A
Index
Number
Optical
Properties

-1

1
2
3
4
5
6
7
8
9

-1

μa (cm )

μs’ (cm )

1.0
0.5
1.0
0.5
1.0
1.5
0.5
1.0
1.5

10
15
15
18
18
18
20
20
20

Of the four phantoms measured, three displayed a downward sloping, negative correlation
between µa and µs’ (see Figure 3.3). The concentration of data points, however, appears to be
random between phantoms. Each set of data for each phantom was fitted using the known
optical properties of that phantom as the initial guess for the optimization algorithm.
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(a)

(b)

(c)
Figure 3.3: µs’ vs. µa of measured phantoms
(a) Resulting optical properties from four concurrent measurements
measurements,, where each measurement has five frames with
-1
-1
data being collected by nine detectors for Phantom A (µa=1.2 (cm ), μs’=16.5 (cm )).. For this set of measurements
the data points are randomly, but relatively evenly distributed about the actual optical properties of the phantom. (b)
-1
-1
Resulting optical properties from four con
concurrent measurements for Phantom B (μa=1.22 (cm ), μs’=18.0 (cm )). For
this set of measurements the data points are more concentrated at μa above the actual value of the phantom and
above the known μs’. (c) Resulting
lting optical properties fro
from four concurrent measurements for Phantom C (μa=1.0 (cm
1
-1
), μs’=25 (cm )).. For this set of measurements the data points are evenly distributed about the actual optical
properties of the phantom but display a greater range in o
optical
ptical properties than the previous two phantoms.

From our fitting process, using a range of initial guesses, we found overwhelmingly that
for ideal, homogeneous data the initial guess given to our fitting algorithm has less effect on the
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final result of the fitting algorithm than the experimental variation in the measurement (see
Figure 3.4).While
While providing the algorithm with an incorrect initial guess does shift the resulting
fitted optical properties about the actual values, it does not result in fitted optical properties
that are greater than 10% different from μs’ and 11% different from μa.

(a)

(b)
Figure 33.4: Optical properties from fitting algorithm for phantom A

(a) Range of optical properties for a range of initial guess used in fitting algorithm. Initial guesses are denoted by the
green squares (for values of initial guesses, see Table 3.2). Resulting value
valuess of optical properties are denoted by small,
-1
-1
colored markers clustered about the known values of μa=1.2 (cm ) and μs’=16.5 cm ). (b) Zooming in on the spread of
optical properties generated by the range of initial guesses plotted in Fig.(a). Note that m
many
any data points are layered
on top of each other for different initial guesses as the resulting values do not change. Actual values of μa and μs’ of
Phantom A is denoted by the large red dot.

3.3.2 Diffuse reflectance
tance spectrally resolved fittin
fitting
Using a radially resolved fitting algorithm allows us to determine the optical properties
of the measured tissues directly. In the past, the resulting optical properties were used to
determine the concentration of common absorbers such as hemoglobin and deoxyhemoglobin
deoxyhemog
indirectly[68, 119, 121].. By building on the wor
work of Finlay and Foster[80],, implementing a
spectrally resolved fitting algorithms allows the direct determination of absorber
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concentrations. This technique also uses the diffusion P3 hybrid-model to model light
propagation in tissue (see A.1 for full derivation and application). Using this model and the
determined values of µa and µs’ (as described below), the diffuse reflectance is calculated at
each wavelength to create entire theoretical reflectance spectrum.
The fitting process results in a vector a, whose components characterize the reflectance
spectrum being analyzed. The first two components of a describe the absorber concentrations in
the measurements of interest[83]:
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The absorption spectra of hemoglobin (Hb) and deoxyhemoglobin (HbO2) taken from the
literature[122]. The coefficients a1 and a2 are the concentrations of HbO2 and Hb respectively.
Only HbO2 and Hb are considered when computing the absorption of a tissue measurement as,
for the studies in this work, all measurements were made on internal organs where whole blood
is expected to be the dominant absorber. The remaining two components of vector a describe
the scattering, according to an approximation based on Mie theory[85]:
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The parameter a3 is the value of µs’ at λ0, the normalization wavelength. The normalization
wavelength is chosen to be the treatment wavelength.. The parameter a4 is determined by the
specific distribution of scatterers and varies from 0.37 for particles much larger than λ to 4.0 for
particles much smaller than λ.
From the vector a, a theoretical reflectance spectrum is created and fitted to the
measured spectrum. Using the optimization function fminsearch as before, the fitting process
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runs through iterations until an optimum theoretical spectrum is determined. The four
components of a are stored and taken to be the best fit values for concentrations of HbO2 and
Hb, and reduced scattering. The quantities HbO2 and Hb, given in µM, are often best expressed
in terms of total hemoglobin and the oxygenation saturation. Using the hemoglobin oxygen
saturation equation:
%
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The fitting process gives [Hb] and [HbO2]; using these results and eqn.( 3.4 ) we determine StO2.

3.3.3 Fluorescence spectra fitting for Photosensitizer concentration
The measured fluorescence spectra are a combination of the fluorescence of several
fluorophores present in the tissue. Photosensitizers such as BPD and HPPH each have a
distinctive fluorescence spectrum. By fitting the measured fluorescence spectrum of a tissue
that is injected with a photosensitizer, before and after treatment light is applied, we are able to
observe the change in the amount of photosensitizer present. A measured fluorescence
spectrum of tissue where a photosensitizer is present must also use the autofluorescence
spectrum (see 3.4.1 Autofluorescence), in addition to the photosensitizer spectrum to
accurately to fit for phototsensitizer concentration. Corrections for the effects of absorption and
scattering in the tissue are also applied to obtain the true fluorescence spectrum of a
photosensitizer.
We used the fitting algorithm developed by Finlay et al.[123] to obtain photosensitizer
concentrations from fluorescence measurements. The measured fluorescence spectrum is
divided by the corresponding reflectance spectrum to account for the effects of absorption and
scattering [124]. The spectrum is then fitted as a linear combination of fluorescence basis
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spectra using a single value decomposition (SVD) algorithm in MATLABTM. The SVD fitting
algorithm is a non-iterative process, unlike fminsearch. The goal of the algorithm is to minimize
the χ2 of the fit:
F}

%

% ,

( 3.5 )

where A=(1/σ)X with X as the basis matrix and σ representing the uncertainties of the
measurements, a is a vector of amplitudes of the vectors to be determined by the fit, and
b=(1/σ)y, where y is the vector of the measured data. These basis vectors are not necessarily
orthogonal, providing the motivation to use the SVD method over the traditional least squares
fitting technique. Press et al. [125] provides an application of SVD fitting, which we will outline
below.
The singular value decomposition of matrix A from eqn. ( 3.5 ) is defined in the following
manner:
F

  ,

( 3.6 )

where U is an orthogonal matrix, w is the diagonal matrix whose elements are the singular
values of decomposition, and VT is the transpose of the orthogonal matrix, V. The goal of SVD
fitting is to determine a matrix A that minimizes χ2. The amplitudes of the fits are related to Eqn.
( 3.6 )via:
}

  .

( 3.7 )

The variances of the amplitude of a (Eqn.( 3.7 )) are expressed in terms of V and m:
?

  .
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( 3.8 )

The uncertainty of a is determined by taking the square root of the elements of va. The matrix m
is the diagonal matrix whose elements are the inverses of the corresponding elements of w. If
the matrix A is singular, a substitution of m with m* (defined below) is made to complete the
fitting process. The elements of matrix m* are defined as:

mi* =

1
, wi > wmaxγ tol
wi

mi* = 0, wi < wmaxγ tol
where wmax is the largest element of w and γtol is a cutoff tolerance that is predetermined. The
choice of γtol can vary, as the resulting fit from an inappropriate choice of γtol is very poor. An
appropriate choice of γtol is one where χ2 is at its minimum for a, (see Figure 3.5) this way we are
able to determine a matrix A and vector a, whose values minimize χ2 and result in the best fit, a,
to the data, y.

Figure 3.5: L-Curve of a typical in vivo fluorescence spectrum
The best choice of γtot gives a fit where we are in the lower left-hand corner of the L-curve [83].

51

While the photosensitizer and autofluorescence are the dominant fluorophores in most
measured spectra, a 61-term Fourier synthesis is included to account for unknown fluorophores
whose fluorescence will affect the measured spectrum. The fluorescence emission spectrum is
well approximated by a sum of Lorentzian curves. With this in mind, the Fourier transform of a
Lorentzian is a decreasing exponential, allowing us to assign an appropriate weight to the
Fourier components such that it decreases with increasing wavenumber. An added benefit of
this method is that low weighting of higher frequency Fourier terms filters out high-frequency
noise present in the data. In the fluorescence fitting process, the Fourier component is given
much lower weighting (usually weight by 2.0) relative to that of the photosensitizer and
autofluorescence (usually weighted by 100). Bringing these fitting components together, the
total fluorescence is determined by:
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Where Ai and fi(λ) are the amplitude and basis spectrum of the ith of N total fluorophores
present, respectively. The value of 20 in the exponentially decreasing weights was determined
empirically[83]. And the spectral amplitudes, Ai, Bk, and Ck ,are returned by the algorithm. These
three amplitudes are the concentrations, in arbitrary units, of the photosensitizer,
autofluorescence, and Fourier components.
To summarize, the measured fluorescence spectrum is divided by the corresponding
reflectance spectrum to account for the effects of absorption and scattering. The spectrum is
then fitted using the technique described in section 3.3.2, only using the SVD algorithm in place
of fminsearch. Basis spectra of autofluorescence and photosensitizers are needed to fit the data
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and isolate the fluorescence spectrum of the photosensitizer, which provides the drug
concentration in the measured tissue. In addition to this, adding in Fourier components is
necessary to account for unknown fluorophores.

3.4 Fluorescence Basis Spectra
3.4.1 Autofluorescence
Many tissues display an inherent fluorescence, even without the presence of an added
fluorophores such as a photosensitizer. Naturally present components, such as Nicotinamide
adenine dinucleotide phosphate (NADPH), which is present in all living tissues, are fluorophores
themselves. When obtaining our basis spectra and analyzing our measured fluorescence data it
is imperative we account for the autofluorescence of the tissue. While the intensity of
autofluorescence varies from tissue to tissue, these differences are minor. The autofluorescence
can thus be measured on one type of tissue and then subsequently applied to all other
fluorescence measurements.
To obtain this autofluorescence spectrum we conducted a series of measurements on
two female nude mice. The mice were previously untreated and had not yet been administered
the photosensitizer. A series of eleven measurements were made on Mouse 1 on the tail,
haunch, and shoulder with a small probe similar in design to the one described in 3.2
Instrumentation. The fluorescence data was divided by the corresponding reflectance data to
account for the effects of absorption and scattering. In processing these measurements, the
mean was taken over all eleven measurements. From this mean spectrum, a scaled spectrum of
protoporphyrin IX (PPIX) (0.4 times the normalized spectrum) was subtracted to remove a peak
observed around 637 nm. A second peak around 676 nm was observed; to correct for this
unexpected peak a Gaussian with a full width half max of 20 and maximum peak of one, scaled
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by 900 was also subtracted from the mean spectrum. The resulting autofluorescence spectrum
(Fig. 3.4) is a smooth spectrum, decreasing with wavelength. This autofluorescence spectrum is
used in the determination of all following fluorescence basis spectra and fluorescence data in
the BPD and HPPH studies.

3.4.2 BPD Basis Spectrum
The basis spectrum of BPD used for data analysis was obtained from the treatment of
two female, untumored, nude mice. Mice were anesthetized by inhalation of isoflurane in
medical air (VetEquip anesthesia machine, VetEquip). Measurements were made on each
mouse before drug administration on the tail, haunch, and shoulder (the treatment site). After
being given a tail injection of 0.25 mg/kg BPD, the mice underwent a half hour drug-light interval
and were treated with a 1 cm diameter laser-beam size (laser was placed 8 cm away from the
treatment site) at a power of 58.9 mW. Measurements were made at before and after light
delivery (treatment time was 55 minutes and 33 seconds) and at 5-minute intervals, causing
brief interruptions in treatment. The data was corrected for CCD integration time and
background was also subtracted before dividing the data by the corresponding reflectance to
account for tissue optical heterogeneity.
The autofluorescence spectrum determined in section 3.4.1 was then subtracted from
pre-treatment averaged measurements made at the treatment site, when the fluorescence
amplitude is greatest. After this subtraction, a small peak was observed around 637 nm. We
identified this peak to be similar to the fluorescence spectrum of the photosensitizer PPIX. A
scaled PPIX basis spectrum (normalized basis spectrum multiplied by 0.4) was then subtracted
from the measured BPD basis spectrum to obtain the spectrum used for data analysis (see
Figure 3.6).
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Figure 3.6:: Autofluorescence and BPD basis spectra measured in nude mice
The autofluorescence was measured and processed as described in Section 3.4.1. The BPD basis spectra collected
from nude mice demonstrates the characteristic fluorescence peak at 690 nm and normalized to 1 by dividing the
whole spectrum by its maximum.

3.4.3 HPPH Basis Spectrum
To determine the fluorescence basis spectrum of HPPH, the procedure described above
is performed, using HPPH1. The basis spectra used for data analysis were obtained
btained from the
treatment of three nude mice with HPPH. Measurements were made on each mouse before
drug administration on the tail, haunch, and shoulder (the treatment site). After being given a
tail injection of 0.25 mg/kg of HPPH, the mice underwent a twenty-four drug-light
light interval and
were treated with a 1 cm diameter laser
laser-beam
beam size at an irradiance of 75 mW/ cm2 to a total
fluence of 135 J/cm2 (55.5 min)
min). Measurements were made on each mouse before and after
light delivery. The final mouse treated ((Mouse
Mouse Three) was measured at 10 minute intervals
1

A study was performed, analyzing if the presence of difference solvents affected the HPPH basis

spectrum. See

A.2 )
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during treatment. The data was corrected for CCD spectral response and detector background
signal. The effect of absorption and scattering were accounted for by dividing the fluorescence
data by the corresponding reflectance data.
The autofluorescence spectrum is subtracted from the averaged measurements of the
treated mice. The measurements were made at the treatment site pre-light delivery to obtain
the HPPH basis spectrum (resulting spectrum is an average of 6 measurements, 6 pre treatment)
when the fluorescence has its greatest amplitude. To confirm how consistent our HPPH basis
spectrum from Mouse 1 is, we fitted the post-light delivery measurements made at the
treatment site from Mouse 2 and 3 (see Figure 3.7) to obtain fits using a singular-value
decomposition algorithm (discussed in greater detail below) for the HPPH fluorescence and
autofluorescence.

Figure 3.7: Fitted HPPH fluorescence data measured in nude mice as a function of wavelength (nm)
The Fourier component is used to account for any abnormalities that are not easily fit by the autofluorescence and
HPPH basis spectra.
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As observed in Figure 3.8 we are able to consistently obtain good fits using our HPPH
spectra. As a further check our basis is compared to measurements made in a cuvette by Sunar
et. al. [25](see Figure 3.8), where there is good agreement. The resulting HPPH spectrum from
our mouse study is used for the fluorescence data analysis for all human in vivo data.

Sunar et al.
HPPH Basis Spectrum

Fluorescence (norm.)

1.2
1
0.8
0.6
0.4
0.2
640

660

680
700
Wavelength (nm)

720

740

Figure 3.8: Measured HPPH basis spectrum compared to spectrum available in the literature
The two spectra agree within the error bars of the measured spectrum and show the characteristic fluorescence peak
of HPPH.

Several photosensitizers’ fluorescence spectra change throughout treatment due to the
presence of photoproducts caused by chemical reactions induced in the drug. This made a study
of HPPH photobleaching necessary in order to validate our basis spectra. The measurements
made on the treatment site (the shoulder) of Mouse 3 at 5, 10, 25, and 45 minutes during light
delivery (at each time interval three measurements were made at the treatment site) (see
Figure 3.9a) display the expected decrease in HPPH fluorescence, indicating a decrease in the
concentration of the drug. No significant change in spectral shape was observed further
indicating there are no photoproducts induced by irradiation.
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(a)

(b)
Figure 3.9: HPPH concentration over time
(a) Measured fluorescence during PDT in a nude mouse as a function of wavelength (nm). (b) HPPH concentration as a
function of light delivered, demonstrates the expected decrease in HPPH concentration in the mouse.
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Using the fitting algorithm described above, the concentration of HPPH in arbitrary
units was found for each the measurements made during treatment. Plotted as a function of
fluence rate (See Figure 3.9b), we see the expected monotonic decrease of HPPH concentration.

3.5 Measurements: BPD
The spectroscopic methods discussed in section 3.1-3.4 were used to evaluate the
interperitoneal cavity of 15 healthy canines. This data was collected as a part of a pre clinical
trial for the treatment peritoneal carcinomatosis (PC) using BPD.PC has low survival outcome
and is difficult to treat with traditional radiation methods due the number of vital organs that
need to be spared in the peritoneal region. The 15 dogs were given either 0.125 mg/kg or 0.25
mg/kg doses of BPD four hours before light administration (See Table 3.3)
Table 3.3: Treatment groups for BPD study
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The dogs were kept in darkened rooms before light administration and all lighting in the
operating room was covered by thin sheets of polyester filter (GamColor #480, GAM, Los
Angeles, CA). The purpose of this filter is to reduce the light intensity at the peak absorption of
BPD to avoid activation of BPD outside the treatment field. Light was administered using 8W
diode laser with a peak at 690 nm (B&W Tek). The light administration procedure was similar to
that described previously in [126]. The mesentery and small bowel were irradiated piecewise
using a light field projected by a microlens. The cavity and the remaining organs were
subsequently irradiated using a diffusing light wand, which was moved throughout the cavity to
ensure uniform distribution of light. The total fluence delivered to the tissue surface was
monitored by isotropic detectors placed on the surface of each section of the bowel, and at
seven locations in the cavity: 1: the right upper quadrant lateral to the liver, near the border of
the diaphragmatic attachments, 2: the left upper quadrant similarly near the border of the
diaphragmatic attachments, 3: the left lower quadrant in the paracolic gutter, 4: the right lower
quadrant, and 5: the pelvis anterior to the dome of the bladder.
Of the 15 canines, we obtained pre and post treatment measurements for 13.
Measurements were made using the probe described in section 3.2 and the data was processed
and fitted accordingly. The optical properties shown in Figure 3.10 and Figure 3.11 were
obtained using the radially resolved fitting algorithm, taking the averages of µa and µs’ between
685 nm to 695 nm, over the first four source-detector separations. The values for
deoxyhemoglobin (Hb), oxyhemoglobin (HbO2), total hemoglobin, and oxygenation were
obtained by taking the average of the first four s-d separations with a wavelength range of 600800 nm, using the spectrally resolved fitting algorithm. Total hemoglobin levels above 2500 uM
were not included as hemoglobin levels above 2500 uM are unphysical[127]. BPD
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concentrations shown in Figure 3.14 were obtained by fitting the first s-d separation spectrum
using the fluorescence-fitting algorithm described above, and then dividing the BPD amplitude
by the corresponding autofluorescence component to account for autofluorescence variation
between subjects and tissue type. The variation in the fluorescence spectra caused by different
µa and µs’ was accounted by dividing by the corresponding reflectance measurements We were
unable to obtain fluorescence spectra for spleen tissue due to the high µa of the tissue.

3.6 Results: BPD
The tissues with measured spectra in the fifteen canine interperitoneal cavities are as
follows: abdominal wall (Abdwall), aorta, bladder, bowel, colon, gall bladder, kidney, liver,
rectum, and stomach. As observed in Figure 3.10 and Figure 3.11, the optical properties vary
greatly, not only between different tissue types but also between different canine subjects. The
optical properties also did not demonstrate any significant trend in changes post PDT. While
relative ranges of tissues type observed, such as liver tissue demonstrating high µa and bladder
tissue to have overall higher µs’, the great variation of optical properties in all tissues points to
the need for real-time spectroscopy to truly calculate the most effective fluence dose not only
for each subject, but also for each tissue type. This variation in optical properties is greater than
the 10% variation observed in our phantom studies, and thus is assumed to be real variation,
rather than variation caused by our fitting algorithms. Table 3.4 and Table 3.5 list the minimum
and maximum values for µa and µs’ respectively for different tissue types.

61

Table 3.4: Minimum and maximum values for µa for BPD at 690 nm

Abdominal Wall
Aorta
Bladder
Bowel
Colon
Gall Bladder
Kidney
Liver
Rectum
Spleen
Stomach

Minimum
(cm-1)
0.0011
0.001
0.001
0.002
0.051
0.007
0.0537
0.0114
0.0058
0.106
0.01

Maximum
(cm-1-)
0.245
0.533
0.976
0.315
0.602
0.897
0.579
1.080
0.145
1.400
0.149

Table 3.5: Minimum and maximum values for µs’ for BPD

Abdominal Wall
Aorta
Bladder
Bowel
Colon
Gall Bladder
Kidney
Liver
Rectum
Spleen
Stomach

Minimum
(cm-1)
0.859
2.023
3.660
1.680
3.530
3.900
13.500
2.030
1.470
17.500
2.090

Maximum
(cm-1)
14.600
21.300
33.500
21.000
27.800
66.230
29.100
82.600
12.900
50.600
34.900

Figure 3.12 and Figure 3.13 also demonstrate wide-ranging variation. In Figure 3.12,
there is no trend in changes in [Hb]tot post PDT. This indicates to us that PDT does not cause
tissues to become hypoxic, which is a desirable clinical outcome. Again, the wide variation in
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[Hb]tot between tissue types and subjects indicates real-time spectroscopy is necessary to truly
know how PDT affects the [Hb]tot of a subject. The StO2 levels (Figure 3.13) are of interest to us
as they provide a way to measure photochemical oxygen consumption and vascular
oxygenation. Figure 3.13 shows us PDT does cause significant vascular damage in the treated
tissues. This is another desired clinical outcome as vascular hypoxia can cause tissues to be
resistant to the more traditional cancer treatment methods: chemotherapy and radiotherapy.
The number of different canine subjects with a measurement for a specific tissue type is listed in
parentheses on the axis of Figure 3.10-Figure 3.14.
The concentration of BPD in tissues pre and post PDT (see Figure 3.14) demonstrates
perhaps the widest range in determined values. While very generally we can observe that BPD
concentration appears to decrease post PDT, this change is smaller than the overall variation in
BPD concentration of different tissues and is therefore insignificant. This method of
fluorescence spectroscopy, then, is too highly variable for use as a form PDT dosimetry. We
observe no systematic photobleaching, further demonstrating how great this variation is.
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Figure 3.10: In vivo absorption coefficient: Pre and Post PDT in canine BPD mediated PDT
The pre PDT data (red) and post PDT data (blue) for each tissue type. The number of subjects for each tissue type are listed along the x-axis in parentheses. The individual data
th
th
points are represented by gray circles. The box above the black line indicates the 75 percentile of the data, while the lower half represents the 25 percentile of data.
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Figure 3.11: Reduced scattering coefficient pre and post PDT for canine BPD-mediated.
The pre PDT (red) and post PDT (blue) data for each tissue type. The same tissues that demonstrate higher absorption also demonstrate higher reduced scattering. The pre PDT
data (red) and post PDT data (blue) for each tissue type. The number of subjects for each tissue type are listed along the x-axis in parentheses. The individual data points are
th
th
represented by gray circles. The box above the black line indicates the 75 percentile of the data, while the lower half represents the 25 percentile of data.
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Figure 3.12: [Hb]tot in Canine interperitoneal cavities
The total hemoglobin of pre (red) and post (blue) PDT measurements obtained using spectral fitting. The pre PDT data (red) and post PDT data (blue) for each tissue type. The
number of subjects for each tissue type are listed along the x-axis in parentheses. The individual data points are represented by gray circles. The box above the black line
th
th
indicates the 75 percentile of the data, while the lower half represents the 25 percentile of data.
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Figure 3.13: StO2 in canine interperitoneal cavities pre and post PDT.
The pre PDT data (red) and post PDT data (blue) for each tissue type. The number of subjects for each tissue type are listed along the x-axis in parentheses. The individual data
th
th
points are represented by gray circles. The box above the black line indicates the 75 percentile of the data, while the lower half represents the 25 percentile of data.
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Figure 3.14: In vivo BPD concentration in canine interperitoneal cavities pre and post PDT
The concentration of BPD pre (red) and post (blue) PDT determined from in vivo fluorescence measurements. The pre PDT data (red) and post PDT data (blue) for each tissue
type. The number of subjects for each tissue type are listed along the xx-axis in parentheses. The individual data points are represented by gray circles. The box above the black
th
th
line indicates the 75 percentile
ntile of the data, while the lower half represents the 25 percentile of data.
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3.7 Measurements: HPPH
3.7.1 HPPH study introduction
The same probe design described in section 3.2, and fitting algorithms used in section
3.6, we’re used to collect data in-vivo in humans who were enrolled in the Phase I HPPH study
first introduced in Chapter 1. The Phase I HPPH-mediated PDT study enrolls patients whose
cancer is detected radiographically and is limited to a single hemithorax with pleural
dissemination and whose pleural malignancy could be resected to a maximal thickness of 0.5
cm. All patients gave informed consent. The main objective of this study is to determine the
maximum tolerated HPPH-mediated PDT dose in patients with pleural malignancies.

Figure 3.15: Detectors sutured into the thoracic cavity
a. Isotropic detector sutured in to the patient’s chest wall and b. Anatomy of the thoracic cavity of the 8 isotropic
detectors during pleural PDT: (1) Apex; (2) Anterior diaphragmatic sulcus (AS); (3) Posterior diaphragmatic sulcus (PS);
(4) Pericardium (Peri);(5) Anterior chest wall (ACW); (6) Posterior chest wall (PCW); (7) Posterior mediastinum (PM);
(8) Diaphragm (Diaph).[128]

The drug was first administered at a dose of 4 mg/m2 and applied light fluence of 15
J/cm2. Over the course of the study the light fluence was escalated to 60 J/cm2 where the
fluence was monitored by optical detectors sutured into the thoracic cavity of the patient (see
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Figure 3.15). After debulking, the thoracic cavity was filled with a dilute Intralipid solution
(0.01%) to facilitate more homogeneous delivery of light to the pleural walls. Light provided by a
diode laser (B&W TEK, Inc. Newark, De) of 661 nm or 665 nm2 was applied using a flat cut
optical fiber (Medlight SA, Switzerland) sheathed within a endotracheal tube, where the balloon
cuff was also filled with an Intralipid solution at 0.1% concentration. This delivery method was
used to avoid burning tissues and protect the pleural walls (see ). Spectroscopic measurements
were made pre and post light application, as in the BPD study (Section 3.5).

Figure 3.16: Application of light to the thoracic cavity during surgery.
A patient’s thoracic cavity being treated with PDT in the clinic. Before the laser is turned on the isotropic detectors are
sutured in a various points through the cavity after the bulk tumorous tissue is removed.

2

The study began using the 661 nm laser, but after a study was done on the 665 laser (see A.3),
this laser was put into use.
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3.7.2 Spectroscopy measurements
The absorption coefficient, µa (cm-1), and reduced scattering coefficient, µs’ (cm-1), were
obtained by fitting reflectance spectra from the first four source-detector separations from 660
nm to 670 nm. The resulting values, seen in Figure 3.17 and Figure 3.18 are the average of µa
and µs’ from the four spectra respectively. We did not observe systematic differences in µa and
µs’ between measurements taken before and after irradiance. Figure 3.17 and Figure 3.18 show
all values for µa and µs’ respectively, with pre and post irradiance values plotted together. The
number of different patients’ tissues used to make each plot are listed in parentheses along the
x-axis. It is interesting to note that lung tissue displays higher values for µa overall. The serratus
tissue, on the other hand, shows lower overall µa.
Reflectance fitting was used to determine values for [Hb]t that were above 2500 uM
were not included in Figure 3.19 as values above 2500 uM are beyond the physical range of
[Hb]t [127, 129]. While Figure 3.19 does display several data points well above the upper
quartile of each tissue, overall data points are concentrated within the lower and upper
quartiles, demonstrating that while there is patient to patient variation, each different tissue
type has a distinct range of [Hb]t levels. As with the optical properties, there is no observable
systematic difference between pre and post irradiance [Hb]t levels. This holds true for StO2
levels, seen in Figure 3.20 as well. Here the data points are more widespread, indicating that
oxygenation levels vary greatly both between patients and between different tissue types.
Although, it can be observed that lung tissue does tend to have lower oxygenation levels than
the surrounding tissues.
The measured fluorescence data, fitted for HPPH concentrations, is displayed in Figure
3.21. Only the spectrum from the first source-detector distance was fitted, as this spectrum had
71

the strongest signal and minimal noise. Data was fit from 600 nm to 790 nm and each fitted
spectrum was divided by its corresponding autofluorescence spectrum to account for variation
in autofluorescence between patients. Figure 3.21 shows that generally, HPPH levels are lower
post irradiance, though this is not observed in all cases.

3.8 Results: HPPH
As in the BPD study in canines, the optical properties in Figure 3.17 and Figure 3.18
show great variation and no trend in changes of optical properties post PDT versus pre PDT. For
clinical cases this result is particularly important. Current treatment protocol prescribes the
fluence dose at a set level for all patients, as well as for all tissue types, based on the assumption
that all tissue is optically homogeneous and the geometry of the target tissue does not affect
overall fluence. Clearly Figure 3.17 and Figure 3.18 show there is great inhomogeneity between
patients and between tissues. Assuming the target tissue is optically homogeneous, then, is
quite unrealistic. For the most accurate fluence dose, these inhomogeneities must be accounted
for, as light will penetrate into the different target tissues at substantially different amounts,
resulting in non-uniform PDT treatments. As stated earlier, the observed variation is greater
than the variation generated by our fitting algorithms and thus is real variation that must be
accounted for. Table 3.6 and Table 3.7 list the minimum and maximum values for µa and µs’
respectively for different tissue types.
Figure 3.19 plots the [Hb]tot for the tissues measured, pre and post PDT.
Generally, [Hb]tot decreases post PDT, but this is not observed in all cases (such as the
esophagus) and the decrease in [Hb]tot is neither uniform nor statistically significant. The overall
range in [Hb]tot does not display a trend, as the spread of values is different for each tissue type
and also does not display a trend pre versus post PDT. This high variability indicates a need to
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monitor [Hb]tot levels throughout treatment as each patient and tissue type is unique. Figure
3.20 shows that, generally, StO2 decreases after PDT, but in no systematic or predictable way.
Again we see the wide-ranging variability. The observed decrease in StO2, however, is not great,
demonstrating the PDT in the thoracic cavity does not cause tissue to become hypoxic, as
observed in the canine study.
The HPPH concentration, plotted in Figure 3.21, continues to exhibit wide-ranging
variability between tissue types and patients. As in the BPD canine study, this method of
monitoring drug concentration does allow us to determine a model that would reliably predict
drug concentration post PDT. As no systematic photobleaching is observed, the motivation for
patient-by-patient drug concentration measuring becomes clear, particularly in light of the
observed inhomogeneity.

Table 3.6: Minimum and maximum values for µa for HPPH

Aorta
Chest wall
Diaphragm
Esophagus
Lung
Pericardium
Serratus

Minimum Maximum
(cm-1)
(cm-1)
0.002
0.950
0.001
1.147
0.004
2.517
0.036
0.649
0.062
2.517
0.005
1.519
0.004
0.577
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Table 3.7: Minimum and maximum values for µs’ for HPPH

Aorta
Chest wall
Diaphragm
Esophagus
Lung
Pericardium
Serratus

Minimum Maximum
(cm-1)
(cm-1)
2.080
51.712
2.080
27.661
2.170
57.886
10.679
50.529
14.355
61.624
11.015
52.754
2.341
35.431

Figure 3.17: In vivo absorption coefficients measured in the thoracic cavities of humans for HPPHmediated pleural PDT
The number of patients for each type of tissue is listed in parentheses along the x-axis. The mean value of µa is
indicated by the line across the middle of each box, with the upper and lower quartiles determining the size of
each box. The pre PDT data (red) and post PDT data (blue) for each tissue type. The number of subjects for each
tissue type are listed along the x-axis in parentheses. The individual data points are represented by gray circles. The
th
th
box above the black line indicates the 75 percentile of the data, while the lower half represents the 25 percentile
of data.
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Figure 3.18: In vivo reduced scattering coefficients measured in patients for a variety of tissues.
The number of patients for each type of tissue is listed in parentheses along the x-axis. The mean value of µs’ is
indicated by the line across the middle of each box, with the upper and lower quartiles determining the size of
each box. The pre PDT data (red) and post PDT data (blue) for each tissue type. The number of subjects for each
tissue type are listed along the x-axis in parentheses. The individual data points are represented by gray circles. The
th
th
box above the black line indicates the 75 percentile of the data, while the lower half represents the 25 percentile
of data.
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Figure 3.19:: In vivo [Hb]tot (uM) measured in the thoracic cavity of patients
Pre (red) and Post (blue) PDT measurements for [Hb]tot. The number of patients for each type of tissue is listed in
parentheses along the x-axis.
axis. The mean value of [[Ηb]tot is indicated by the black line across the middle of each box
plot, with the upper and lower quartiles determining the size of each box. The pre PDT data (red) and post PDT
data (blue) for each tissue type. The number of subjects for each tissue type are listed along the x-axis
x
in
th
parentheses. The individual data points are represented by gray circles. The box above the black line indicates the 75
7
th
percentile of the data, while the lower half represents the 25 percentile of data.
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Figure 3.20:: In vivo StO2 measured in the thoracic cavity of patients, pre and post PDT
Pre (red) and Post (blue PDT measurements of StO2. The number of patients for each type of tissue is listed in
parentheses along the x-axis.
axis. The black line indicates the mean value of StO2 across the middle of each box plot, with
the upper and lower quartiles
les determining the size of each box. The pre PDT data (red) and post PDT data (blue) for
each tissue type. The number of subjects for each tissue type are listed along the xx-axis
axis in parentheses. The individual
th
data points are represented by gray circles. The box above the black line indicates the 75 percentile of the data,
th
while the lower half represents the 25 percentile of data.
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Figure 3.21: In vivo HPPH concentration measured in the thoracic cavity of patients, pre and post PDT
Pre (red) and Post (blue) PDT measurements of HPPH concentration. The number of patients for each type of tissue is
listed in parentheses along the x--axis.
axis. The mean value of HPPH is indicated by the line across the middle
midd of each box,
with the red and blue bar representing the middle quartiles. The pre PDT data (red) and post PDT data (blue) for each
tissue type. The number of subjects for each tissue type are listed along the xx-axis
axis in parentheses. The individual data
th
points are represented by gray circles. The box above the black line indicates the 75 percentile of the data, while the
th
lower half represents the 25 percentile of data.

3.9 Discussion
We successfully obtained in
in-vivo optical properties, [Hb]t, oxygenation saturation, and
drug concentration levels for both the canine BPD study and the Phase I Clinical HPPH trial. For
both the BPD and HPPH studies, we determined the optical properties are not significantly
affected by irradiation during PDT. These optical properties varied greatly between different
tissue types, but, with the exception of several outliers, the µa and µs’ of each tissue types
demonstrated a characteristic range between different subjects. These ranges of µa and µs’ can
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inform PDT treatment planning in that we have a relative idea of which tissue types are more
optically absorbing or scattering. The optical properties determined here will be used in fluence
modeling in Chapter 4 and Chapter 5.
Table 3.8: Mean values of in-vivo optical properties for HPPH patients

The [Hb]t and oxygen saturation obtained from our measurements also display great
variation between subjects and tissue types. Utilizing the [Hb]t and oxygen saturation to
determine treatment outcome is beyond the scope of this work. However, our determined
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values of [Hb]t and oxygen saturation will add new information to the work of others whose
work focuses on the effects of total hemoglobin and oxygen saturation on treatment outcome
and how these quantities can be used to improve PDT treatment planning. The determined
concentrations of HPPH help to monitor the behavior of the photosensitizer during irradiation.
From the results of the BPD and HPPH studies, we find generally, photosensitizer concentration
decreases after irradiation. This outcome is expected, the activation of the photosensitizer when
it is irradiated utilizes the drug to induce tissue damage. As observed in Figure 3.14 and Figure
3.21, photosensitizer remains in the tissue. The drug remaining in the tissue affects the
photosensitivity the subject will experience post treatment.
Accounting for the great variation in all measured quantities in the two studies
presented here shows the great need for real time, in vivo measurements during treatment. A
fluence dose determined in this way is a large step from the current fluence dose protocol,
which is based on a optically homogeneous, semi-infinite medium model. While the initial
survival outcomes from the HPPH study are promising, it would be most interesting to observe
how PDT treatment, tailored to each patient’s unique properties, affect treatment outcome.
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Chapter 4

Light Distribution Modeling
4.1 Introduction
The spectroscopy data presented in the preceding chapter provides only one element of
several for optimizing PDT light dosimetry. As discussed by Zhu and Finlay [23], light fluence is
currently based on both the incident light as well as received at the tissue surface. The total light
distribution in the treatment tissue is a function, in part, of the tissues’ properties, as
determined in Chapter 3, and also a combination of direct and scattered light (note that factors
such as tissues oxygenation are also important to PDT dosimetry, but are beyond the scope of
the work presented here). Several PDT dosimetry systems attempt to monitor incident and
scattered light at the tissue surface or interstitially [23, 24, 26, 130, 131], but light distribution
modeling serves as a potential tool to optimize treatment planning. This chapter presents
several studies of light distribution modeling in different geometries, building upon the work of
existing methods[5, 43-45, 56].
MC simulations are a standard method of photon transport modeling[43, 132] and
frequently used to verify analytic models. Beginning with the simplest scenario, we consider the
fluence modeling in a semi-infinite media and improve upon existing empirical solutions[133]
using Monte Carlo simulations (MC) for varying light field sizes. From the semi-infinite geometry
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we move on to simulations in a spherical cavity. The expanded theory of fluence in a spherical
cavity is compared to MC simulations of a spherical air cavity for a range of optical properties.
We find in the presence of an attenuating medium Star’s analytic solution no longer holds true
and MC results are compared to an empirical solution. Finally, with the view to developing a
fluence model more applicable to the highly asymmetric geometries of the thoracic cavity, we
conduct a series of MC simulations for an oblate ellipsoidal cavity. At present, there is no
analytic solution for cavities that are not radially symmetric in all directions.
The purpose of these studies is to verify the analytic model for fluence against
simulation results previously unreported for light distribution in spherical air cavity geometries
which account for the effect on fluence caused by multiple scattering in the cavity. And also to
explore scenarios for which there is no analytic solution but more closely resemble what is
observed in pleural PDT. The consideration of arbitrary cavity geometries presents a
considerable challenge in modeling light distribution with respect to photon path tracking. The
results of this modeling combined with the in vivo spectroscopy data presented in Chapter 3 are
the first steps to developing patient-specific PDT dosimetry system.

4.2 Semi-Infinite Modeling
Calculating the fluence in a semi-infinite medium is the simplest geometry (beyond an
infinite medium) considered when modeling photon transport and light distribution. The
analytic solution presented in Section 2.3.1 is based on applying the diffusion approximation to
a set of boundary conditions appropriate to a semi-infinite medium, where, unlike fluence in a
cavity, there is no multiple scattering to consider. This solution breaks down, however, when the
reduced scattering coefficient is not considerably greater than the absorption coefficient, as in
the instance of clinical cases where blood is present. To solve analytically for the fluence for a
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semi-infinite medium with greater accuracy, the P3 approximation discussed in section 2.3.2 is
applied[68, 134, 135]. The P3 approximation requires continuity of each moment of radiance at
the boundary. Recall that eqn. ( 2.18 ) describes the fluence for a semi-infinite medium and is a
complicated expression (see A.1 ).
Steve L. Jacques [133] determined a simpler empirical expression using MC simulations
for a collimated light source incident on a planar medium. His expression for the fluence in the
medium for an incident broad beam (radius>2 cm) is:

.P

6 Q @3RSTT ^A ,

( 4.1 )

where S0 is the light source (W/cm), z is the depth of measurement, µeff=(3µaµtr)1/2, and k, the
backscattering coefficient, is given by:
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Where, in relation to eqns.( 4.1 ) and ( 4.2 ), Rd is determined from the simulation results.
Jacques approximated ρ to be [133]:
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The factors in eqns.( 4.2 ) and ( 4.3 ) were determined from a rigorous series of MC
simulations performed by Jacques[133]. In this work, we improve upon constants in eqn.( 4.2 ).
Instead of using eqn. ( 4.3 ), however, we will fit our MC results with ( 2.35 ), as it is a by
obtaining new fits of fluence from our own MC simulations for a semi-infinite medium for
varying circular field sizes, from broad beams to small fields (radius<2 cm).
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4.3 Semi-Infinite Monte Carlo Simulations
4.3.1 Monte Carlo Methods for a Semi-Infinite Medium
Previous work modeled light distributions for broad beam light sources in air or water
incident on semi-infinite media[43, 132, 133]. In PDT, however, often the treatment of surface
lesions require a light field size less than 2 cm in radius[136]. The total fluence rate is affected by
this small light field size as less light scattering occurs and significantly reduces the fluence in the
medium (recall there is no multiple scattering of light in this scenario). Building upon the work of
Zhu et al. [81, 136], we conduct a series of MC simulations to determine new empirical
expressions for Rd and k for the fluence of small fields sizes. An expression for k and values for µ
(from eqns.( 4.1 ), ( 4.2 ), and ( 2.35 ) ) are fitted for large to small field radius, and these new
values increase modeled fluence accuracy compared to the previously published expressions
determined for broad beam light sources.
The MC simulation is setup using a slab of optical homogeneous medium with infinite
length and finite depth that is surrounded by air according to the method developed by Zhu et
al. [81]. The indices of refraction of the tissue medium and air are 1.4 and 1 respectively. The
absorption and reduced scattering coefficients of the simulation medium were varied according
to Table 4.1.
For scoring efficiency, the light source is a pencil-beam that is incident on the medium
with varying angle. When calculating the fluence from simulation results, the pencil beam is
convoluted according to eqn.( 4.4 ):
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Table 4.1: Optical property combinations for MC simulations
-1

-1

Absorption Coefficient (cm )

Reduced Scattering Coefficient (cm )

0.01

5

0.1

5

0.5

5

1.0

5

0.01

10

0.1

10

0.5

10

1.0

10

0.01

15

0.1

15

0.5

15

1.0

15

0.01

25

0.1

25

0.5

25

1.0

25

0.01

40

0.1

40

0.5

40

1.0

40

The pencil-beam kernel is denoted by p and is calculated by the simulation. I is 1 inside
the light field and zero outside the light field. The photons are launched and scattered in the
forward direction (g~0.9)[137], where the photon density, ρn, is scored via cylindrically
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symmetric voxels of 0.01 cm thickness, 0.2 cm width, and 1o size. The recorded ρn is then used
to calculate the fluence per unit incident light power of the light source in the medium using the
number of incident photons, Ninc, as φ=ρn/Ninc/µa.

4.3.2 Semi-Infinite MC Results for ρ and k
The fits for µ, k and ρ were obtained via the fitting process for a non-linear function
using the optimization fitting function from MATLABTM fitfun. The function fitfun utilizes the
MATLABTM function fminsearch (mentioned previously in Section 3.3), which uses an
unconstrained non-linear optimization technique. This function finds the minimum of a scalar
function of several variables of a specified functional form using an initial estimate for the
minimum. The determined minimum is the best-fit value for the scalar in question.

4.3.3 Fitting results k in terms of fluence
Equation ( 4.1 ) is well suited for large field size (radius>2 cm), but this solution for
fluence breaks down at smaller field sizes. In considering smaller field sizes we fit for µ and k:

.P
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Q 3R^ ,

( 4.5 )

The resulting fitted curves are plotted with the MC results using the optical properties listed in
Table 4.1.
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Figure 4.1: MC results for fluence compared to fit with new values for k and µ
Fields size from lower left corner to upper right:
0.1 cm, 0.25 cm, 0.35 cm, 0.5 cm, 1.0 cm, 1.5 cm, 2.0 cm, 3 cm, and 8.0 cm

Figure 4.2: MC results for fluence compared to fit with new values of k for small field sizes
Fields sizes from lower left corner to upper right: 0.1 cm, 0.25 cm, 0.35 cm
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Equation ( 4.1 ) states that φ(x) is a function of k and µeff for broad beams, and by eqn. (
4.2 ), a function of ρ . This relationship holds only for field sizes greater than 2 cm. In generating
Figure 4.2, a new µ had to be fitted for numerically in order to obtain an accurate fit.
Table 4.2 lists µeff for the simulations run (µa listed in the columns, µs’ listed in the rows).
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Table 4.3 lists these new values to replace µeff in eqn. ( 4.1 ) for smaller field sizes, which
generate the curves generated in Figure 4.1 and Figure 4.2∗.
Table 4.2: µeff for the optical properties used in the MC simulations

0.01 cm
5 cm

∗

-1

10 cm

-1

15 cm

-1

25 cm

-1

40 cm

-1

-1

0.387
0.548
0.671
0.866
1.095

0.1 cm

-1

1.225
1.732
2.121
2.739
3.464

0.5 cm

-1

2.739
4.743
4.743
6.124
7.746

1 cm

-1

3.873
5.477
6.708
8.660
10.954

Note that these fits are the results of simulations run for the optical properties listed in Table 4.1
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Table 4.3: Values of µ determined numerically to replace µeff in eqn. ( 4.5 )for small beam sizes

Circular Field Size, radius = 0.1 cm
0.01 cm
5 cm

-1

10 cm

-1

15 cm

-1

25 cm

-1

40 cm

-1

-1

2.021
2.417
2.514
2.799
2.936

0.1 cm

-1

2.336
2.822
3.115
3.434
3.701

0.5 cm

-1

2.844
3.557
4.043
4.744
5.446

1 cm

-1

3.230
4.140
4.753
5.561
6.574

Circular Field Size, radius =0.25 cm
0.01 cm
5 cm

-1

10 cm

-1

15 cm

-1

25 cm

-1

40 cm

-1

-1

2.021
2.417
2.514
2.799
2.936

0.1 cm

-1

2.336
2.822
3.115
3.434
3.701

0.5 cm

-1

2.844
3.557
4.043
4.744
5.446

1 cm

-1

3.230
4.140
4.753
5.561
6.574

Circular Field Size, radius =0.35 cm
0.01 cm
5 cm

-1

10 cm

-1

15 cm

-1

25 cm

-1

40 cm

-1

-1

2.021
2.417
2.514
2.799
2.936

0.1 cm

-1

2.336
2.822
3.115
3.434
3.701

0.5 cm

-1

2.844
3.557
4.043
4.744
5.446

1 cm

-1

3.230
4.140
4.753
5.561
6.574

In the same manner, when fitting ρ we used the functional form of ( 2.35 ), fitting for
parameter c(1), c(2), c(3):

O

}
°1  Q 3I% 43? ± Q I' 43? ,
2

( 4.6 )

where the parameters c(1), c(2), and c(3) were optimized using fitfun. Figure 4.3 shows the fits
obtained from MC results ρ. The resulting fitting parameters for broad beams (radius r larger
than 2 cm) are shown in Table 4.4.
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ρ

ρ

Figure 4.3: ρ as a function of albedo, comparing MC results to model fit for broad circular beams with radius larger
than 2 cm.

Table 4.4 Fitting parameters for Eq. 4.6 for broad beam MC simulated diffuse reflectance ρ and reduced albedo a’.

c(1)
0.941

c(2)
20.389

c(3)
6.614

2

Table 4.5: R between the respective fits to the MC data

Jacques
Zhu and Meo

0.810
0.982
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Figure 4.3 demonstrates the robustness of our fitting process. The functional form for the
backscattering coefficient, k, used for fitting optimization then becomes, with respect to eqn.(
4.2 ):



1 O0%  3

( 4.7 )

The parameters m(1), m(2), and m(3) again were optimized for the best fit of k as a function of

ρ. As shown in Figure 4.4, we obtained a closer fit for k:

ρ

ρ
Figure 4.4: Comparison of MC generated k vs. ρ for broad beams.Symbols are MC simulation. The red line is our new
fit. The blue solid line is taken from Jacques fit Eq. 4.3 [132].
Table 4.6: New Parameters for k as a function of ρ

m(1)
6.8085

m(2)
1.3107
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m(3)
1.9884

The fit for k by Farrell et al. gives an R2=0.974 while our fit gives R2=0.999. This study of fluence
in a semi-infinite medium establishes the validity of our MC simulation methods in the simplest
treatment geometry and our fitting techniques. We determined new constants for Jacques’
empirical models that provide much greater accuracy. The following sections build upon this
work to simulate photon transport in cavity geometries with varying degrees of symmetry,
which more closely simulate treatment regions seen in the clinic.

4.4 Spherical Cavity Modeling
The semi-infinite approach to calculating fluence is most useful for PDT applications
where the treatment tissues are approximated as semi-infinite media. PDT fluence dosimetry
used in topical treatment, such as for skin, is well approximated by the theory discussed in
Section 2.4. In the instance of a treatment cavity geometry, such as the thoracic cavity or the
bladder, scattered fluence exhibits an overall increase beyond predicted by that on a semiinfinite medium, due to photons that are scattered repeatedly into the cavity wall. This
increased fluence is known as the integrating sphere effect (ISE). Total fluence rate at the cavity
wall was observed to increase fluence by nearly a factor of five for an isotropic light source[1]. A
solution to the diffusion approximation for spherical air cavity, then, is needed to most
accurately calculate the true fluence rate at the cavity wall. The analytical derivation for fluence
in a the spherical cavity follows strict diffusion approximation (unlike that used in Star’s original
derivation), based and expanded on solutions available in the literature[3, 7, 8, 69].
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Figure 4.5: Spherical cavity with inner radius r1 and r2

Given a two-layer spherical “slab” with inner radius r1 and outer radius r2 (see Figure
4.5), the expressions for radiant flux F(r) and scattered fluence φs(r) (shown below) first
introduced in Chapter 2, are expressed in the spherical polar coordinates of r, θ, and φ,
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( 4.9 )

Where S(r) is the light source. The radiant flux and scattered fluence are related in the following
way:
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( 4.10 )

( 4.11 )

Using eqns. ( 4.10 ) and ( 4.11 ), eqns. ( 4.8 ) and ( 4.9 ) become eqns. ( 4.12 ) and ( 4.13 )
respectively:
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By symmetry, eqns. ( 4.12 ) and ( 4.13 ) reduce from  to r, the radial distance from the center of
the sphere and become the following:
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( 4.15 )
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We assume the light source, S(r), is an isotropic point source of the form UX Q RgU3UV , where P
is power of the light source. To solve for the fluence both in the inner sphere, i.e., the cavity
surrounding tissue, the distance between r1 and r2, we must solve for the quantities [F+(r)+F-(r)]
and [F+(r)-F-(r)]. Solving eqn.( 4.14 ) for r2[F+(r)-F-(r)] and then substituting this solution into eqn.(
4.15 ) we arrive at an expression for [F+(r)+F-(r)] by multiplying both expressions by r2.
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Plugging this expression for r2[F+(r)+F-(r)] into eqn. ( 4.14 ):
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inhomogeneous differential equation:
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Where S+ and S- equal:
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Recall we want to solve for the scattered fluence in a cavity, φs=2[F+(r)+F-(r)], we can therefore
solve for the quantity [F+(r)+F-(r)]. Equation ( 4.16 ) can be solved for [F+(r)+F-(r)] by taking the
sum of the particular solution and the solutions of the source free equation, multiplied by
constants . These constants will be determined using the appropriate boundary conditions. The
source free equation becomes homogeneous, and is then expressed as:
t%
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The solution to this familiar homogeneous equation takes the form:
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( 4.19 )
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Applying this solution to eqn. ( 4.15 ) gives a solution for [F+(r)+F-(r)]:
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With solution for [F+(r)-F-(r)] determine from the homogeneous equation, it remains for us to
determine [F+(r)+F-(r)] by solving the inhomogeneous equation, eqn.( 4.19 ), where the source is
reintroduced. Let Hb(r)=r[F+(r)+F-(r)]:
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known particular solution of the inhomogeneous equation is of the form:
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To solve the integral in eqn.( 4.21 ), we let 6
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∞. The solution for HB then becomes:
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The coefficient B0 is an exponential integral of the form:
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The solution for B0 is well approximated by a polynomial, which will be of further use as we
come to a complete expression for fluence in a spherical cavity with mismatched indices of
refraction between cavity and the surrounding medium. Combining eqns.( 4.20 ) and ( 4.41 ) we
arrive at an expression for φs=2[F+(r)-F-(r)]:
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It now remains to apply the appropriate boundary conditions and approximations to solve for
the coefficients B+, B-, and B0. The first approximation we make is limUX ³z .

0. This

approximation is reasonable as fluence rapidly decreases as the distance from the light
increases, particularly in an absorbing, scattering medium. To fulfill this approximation, B+=0,
eliminating several terms in eqn.( 4.24 ). We then make the approximation for B0, saying that
6 } ³

` ]¦
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. Equation ( 4.24 ) then simplifies to:
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Recall that we assume µeff<<µt because µa<<µs. This allows us to make the approximation
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Equation ( 4.43 ) then becomes:
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To solve for B- we must return to the boundary condition F+(r1)=F-(r1) and the original differential
equation, eqn.( 4.15 ):
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Solving for B-:
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Using this value for B-, we arrive at a full expression for fluence in the medium surrounding the
spherical cavity:

. 

3 U Q 3RSTT U3Uu
v
4" @1  `cc I A

2 Q 3RgU3Uu
w.
3
%

( 4.29 )

When eqn.( 4.29 ) is evaluated for r=r1 (i.e. at the cavity wall), and recalling the optical
penetration depth is small, µeffr1>>1, it simplifies to:
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To arrive at an expression for the fluence in the cavity, we must introduce the refection
factor, r21. The reflection factor is dependent on the Fresnel coefficients of the medium and the
cavity and requires that light scattering occurs only on one side of the cavity-medium boundary,
meaning there is no scattering present in the cavity. The reflection coefficient is defined as:
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Where θc is the critical angle, θI is the angle of incidence, and Rfres is defined as:
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( 4.32 )

where n1 is the index of refraction of the cavity, n2 is the index of refraction of the surrounding
medium, θR is the angle of refraction, and θi is the angle of incidence. The flux reflected back
into the cavity is then (1-r21)Fr-(r1). The non-scattered fluence in the cavity is the direct light from
the isotropic source, S/4πr12. The scattered light in the air cavity for a centrally located source, is
the total light in the medium, minus the direct light, multiplied by the reflection factor term:
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The total fluence at the cavity wall, inside the cavity is then:
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4.5 Spherical Monte Carlo Simulations: No Attenuation
We conducted a series of MC simulations for a spherical air cavity with a centrally
located isotropic source to verify the fluence model derived in Section 4.4 and to establish our
treatment of multiple scattering within the cavity. We simulate the random walk of photons in
the surrounding medium with a specified mean free path and scattering angle in the medium to
determine fluence at the cavity wall and surrounding tissue can be determined. The absorption
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coefficients and scattering coefficient
coefficients are homogeneous in the surrounding tissue and indices
of refraction are 1 for
or air and 1.4 for tissue.

Figure 4.6: Schematic of a slice of the spherical cavity
The origin of the system is set at the center of the inner sphere (0,0,0), of radius 10 cm. The surrounding medium
(depicted in red), represents the surrounding tissue and is assigned different combinations of optical properties,
uniform over the entire medium.

4.5.1 Monte Carlo Photon Transport Modeling
We developed a MC simulation for a spherical cavity with uniform optical properties and
no attenuation in the cavity (see Figure 4.6) in the MATLABTM platform. This simulation is an
adaption of work done by Zhu et al. [81, 136] which simulated
mulated photon transport for a semisemi
infinite planar surface. A spherical cavity geometry is initialized, with the inner radius set to 10
cm
m and the outer radius set to 15 cm. Each voxel in this geometry is a 0.005 cm x 0.005 cm cube.
As each photon passes through each voxel, the photon’s location and weight are recorded.
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Photons are followed in this manner until they escape the outer radius, or when the photon
weight becomes insignificant. It is this recorded photon density, ρn, that is used in postsimulation analysis to determine the fluence rate. For scoring efficiency, the light source for
the simulation is a pencil beam that is perpendicularly incident on the cavity surface (to
compare results to the diffusion approximation solution, this light source is convolved to an
isotropic point source, as described below). 104 photons were propagated through the
simulation. The photon step size, ∆s, is determined by the optical properties and uniformly
distributed random number, ε: ∆s=mfp-ln ε, where the mean free path, mfp, is defined as
mfp=1/(µa+µs). We assume the tissue surface is Lambertian, therefore the radiant intensity
from the tissue surface follows cos θ for the azimuthal angle, θ [138].
The pencil-beam light source was placed at the cavity-tissue boundary, sending
photons into the surrounding tissue in a concentrated region determined by the size of the
beam (see Figure 4.7). The resulting kernel of the pencil beam is then convolved with an
isotropic point-source (eqn. ( 4.35 )) for comparison purposes with our analytic solution.
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where r is the radius of the cavity, r’ is the location of the photon, and S is the strength of the
light source. The convolution was taken to a standard quadrature sum and the resulting
fluence was then compared with the fluence from our analytic model both within and
without the cavity.
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Figure 4.7: Depiction of MC simulation for a spherical cavity with a pencil beam light source
Results from preliminary run of Monte Carlo simulation for a cavity of inner radius of 10 cm and outer radius of 15
-1
-1
cm, μa=1cm , μs’=18 cm , g=0.9 for a tissue-air interface for a pencil-beam light source located at the center of the
cavity. The fluence for the pencil-beam source is then convolved with the fluence of an isotropic point source for
comparison with our analytic model.

The simulation records the following quantities: the photon density ρn as a function
of emitting angle, the fraction of diffusely reflected photons by the inner radius, the fraction
of diffusely reflected photons by the outer radius, and the kernel as a function of emitting
angle. The light fluence rate, φ, per unit incident light power of the source is taken to be

φ=ρn/Ninc/µa, where Ninc is the number of incident photons. The reciprocity theorem[139] is
used to calculate ratio of the light fluence rate φ to the incident irradiance (or light fluence
rate in air φair) on the central axis of a circular field with radius R by an area integral:

.
.?U

Î


6

Oo

ioI

103

?

2"  .

( 4.36 )

The reciprocity theorem is applied again to calculate the angular distribution of differential
diffuse reflectance, rd, as a function of beam radius and emitting angle, θ. Reflection of
photons at the cavity boundary is modeled according the Fresnel reflection coefficient for
unpolarized light (eqn. ( 4.32 )). The multiple scattering of photons within the cavity,
causing the ISE, is described in the following section.

4.5.2 Multiple Scattering
The MC simulation code developed by Zhu et al. [81, 136] does not account for the
multiple scattering observed in spherical cavities. To accurately simulate the photon migration
the cavity, we added a treatment of multiple scattering to the existing simulation. The multiple
scattering treatment utilizes basic ray tracing, incorporating the Fresnel coefficients for
transmission and reflection for unpolarized light and is described schematically in Figure 4.8. We
consider multiple scattering first for a sphere, whose complete symmetry allows the calculation
of scattering angles to be simplified.
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b
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Figure 4.8: Schematic of multiple scattering treatment in a spherical cavity
The point nxi is the point where two photons interact a distance r0 from the cavity center. The photon which hits the
cavity wall with direction u0, a distance x0 from the cavity center and then travels a distance l and is incident on the
cavity wall with direction ut. See definitions of quantities and the derivation of ut below.

105

4.5.3 Spherical Cavity MC Results for a centrally located source
MC simulations were run for µa=0.01 cm-1, 0.1 cm-1, 0.5 cm-1, 1.0 cm-1 and µs’=5 cm-1, 10
cm-1, 15 cm-1, 25 cm-1, 40 cm-1. 105 photons were launched at an incidence angle of 0o from the
center of the cavity as pencil beam (see Figure 4.6). This light source was later convolved to an
isotropic point source as described in Section 4.5.1. The cavity had a radius of 10 cm, and the
surrounding medium had an outer radius of 20 cm. No attenuation was present in the cavity,
which was treated as air with an index of refraction of 1. Optical properties were uniform
throughout the medium surrounding the cavity. Figure 4.10, Figure 4.11, Figure 4.12, and Figure
4.13 show the comparison of the calculated total fluence and scattered fluence from the cavity
center using eqns.( 4.33 ) and ( 4.34 ) to the results of our simulations.
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Figure 4.9: Bird’s eye view of a photon scattering multiple times off the cavity wall

As one can observe, there is excellent agreement between the calculated fluence in the
cavity and the fluence derived from the MC simulations. The results diverge slightly from one
another with increasing µa, but are still in overall agreement. These results indicate our
treatment of multiple scattering within the cavity is a suitable technique for spherical cavities of
homogenous optical properties. The results from this simulation allow us to determine the
fluence as a function of angle about the cavity, at the cavity-tissue boundary. We observe the
scattered portion of the fluence is uniform, as expected since eqn. ( 4.34 ) is dependent only on
the radius of the cavity.
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(a)

‘’’9b)
Figure 4.10: MC simulated scatter fluence rate per source power (Φs/S) results compared to eqn. ( 4.33 )
-1

Scatter fluence and total fluence for µa=0.01 cm and µs’ = 5, 10, 15, 25 cm-1. (a) Total fluence rate vs. distance from
cavity center. (b) Scattered fluence rate vs angle about entire cavity wall. See corresponding legend below.

108

(a)

(b)
Figure 4.11: MC fluence rate results (Φs/S) compared to eqn.( 4.33 ) and (4.34)
-1

Scatter and total fluence rate, for µa=0.5 cm and µs’ = 5, 10, 15, 25 cm-1. (a) Total fluence rate vs. distance from
cavity center. (b) Scattered fluence rate vs angle about entire cavity wall. See corresponding legend.
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(a)

(b)
Figure 4.12: MC fluence rate results (Φs/S) compared to equation ( 4.33 ) and (4.34)
-1

Comparing scatter and total fluence rate, for µa=0.5 cm and µs’ = 5, 10, 15, 25 cm-1. (a) Total fluence rate vs. distance
from cavity center. (b) Scattered fluence rate vs angle about entire cavity wall. See corresponding legend.
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(a)

(b)
Figure 4.13: MC fluence rate results (Φs/S) compared to equation ( 4.33 ) and (4.34)
-1

Scatter and total fluence rate, for µa=1.0 cm and µs’ = 5, 10, 15, 25 cm-1. (a) Total fluence rate vs. distance from
cavity center. (b) Scattered fluence rate vs angle about entire cavity wall. See corresponding legend.
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4.6 Spherical Monte Carlo Simulations: Attenuation
In the clinic, when treating a patient’s thoracic cavity, several key factors arise that were
not accounted for in the preceding MC simulations. The thoracic cavity is extremely
asymmetrical (see Figure 4.14) with varying optical properties (as seen in Chapter 3).
Furthermore, during PDT treatment, the thoracic cavity is filled with a diluted 0.01% IntrallipidTM
solution to help scatter the treatment light more uniformly. This solution mixes with blood
present, creating an attenuating medium with negligible scattering filling the cavity. Star’s
solution for fluence in an air cavity does not in the presence of attenuation. The effects of an
attenuating medium in a cavity are explored here via MC simulations for a spherical cavity and
later for an ellipsoidal cavity.

4.6.1 Monte Carlo Methods for attenuation
To model photon transport in a cavity in the presence of attenuation is a more
complicated simulation. The MC simulation developed here is a modified version of the code
developed in C by Boas et al. [140]. Their simulation, whose photon transport method is
described in detail by Wang and Jacques[132], is able to track photons as they travel through a
grid laid over the entire geometry with each region able to be assigned its own optical
properties. This tracking method is particularly useful for our purposes, where the simulation
cavity has either no absorption or scattering (no attenuation) or minimal absorption
(attenuating) media. In the simulations discussed in Section 4.5, we did not track the photons in
the cavity, only those in the surrounding medium. By tracking the photon at any point in the
geometry we again further knowledge of how photon transport is affected by different
geometries.
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Figure 4.14: Contour of the thoracic cavity taken during treatment
The blue lines represent the outer contour of the thoracic cavity, while the pink lines represent the movement of the
treatment wand (see Chapter 5). The detectors sutured into the cavity wall are marked.

First, a spherical cavity is initialized with user-specified voxel size (see Figure 4.15). A
photon is launched in a user-specified direction from a given location. To achieve an isotropic
point source, each photon is launched in a random direction from ranging from 0 to 2π from the
center of the cavity (determined by using a uniformly distributed random number). The length
to the first scattering event is calculated using an exponential distribution. Photon absorption is
determined by decreasing the photon weight by e(-μaL) where L is the length the photon
travels[132]. The Henyey-Greenstein phase function is used to determine the new scattering
angle of the photon. The new scattering length of the photon is then determined by an
exponential distribution as before. The photon is propagated this new length in the new
direction. This propagation process continues until the photon exits the medium or the photon
traveled for 10 ns, which at this point, its weight can be regarded as negligible[140]. When a
photon encounters a boundary, the probability of reflection is calculated using Fresnel’s
equation[132]. If the photon is reflected back into the cavity, our multiple scattering treatment
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described in Section 4.5.2 determines the photon’s path in the cavity. An empirical solution for
scattered fluence at a spherical cavity wall is given by eqn.( 4.37 ) [128] for a non-attenuating
cavity:
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Where f is the ratio between the open surface area to total surface area. Since we are only
considering completely closed geometries, f will always equal 0.The factor ρ earlier in chapter 2
(eqn. ( 2.35 )), is defined as:
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Where a’ is the albedo and is defined as a’=µ’s/µ’s+µa. and A is the reflection factor (A=2.9 in this
instance). To account for the attenuation now present in the cavity eqn.( 4.37 ) becomes:
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This term, Q 3R¦ggS UV , describes the exponential decay caused an atenuating medium, described
by µatten . As ρ is also dependent on the optical properties of the system, it stands to reason that
where ever ρ appears, it should be multiplied by the attenuation term. We compare eqn. ( 4.37
)to the MC simulation results for an air cavity, and to eqn.( 4.39 ) when an attenuating medium
is present in the cavity. The total fluence for an attenuating cavity then becomes:
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where r is the position from the source and r1 is the radius of the cavity. The optical properties
of the cavity and surrounding medium are assigned voxel by voxel (each voxel is 1 mm3) and
each photon is tracked voxel by voxel.

Figure 4.15: Visualization of the spherical cavity generated by MATLAB

TM

For plotting purposes the geometry’s size was normalized by the outmost radius. Photons were launched from the
center of this volume. The code used allows the user to track photons at any location. For this study, photons were
tracked at different locations along the cavity-medium boundary, where the red and green spheres meet.

4.6.2 Spherical Cavity MC Results in the presence of attenuation
The MC simulations presented here were performed for spherical cavities of radius 10
cm. 108 photons were launched for each simulation, with the direction of the photon chosen by
a uniformly distributed random number to effect a centrally located isotropic point source. The
absorption coefficient of the surrounding medium ranged from 0.01 to 0.05 and 0.1 cm-1, while
the reduced scattering coefficient was kept constant at 10 cm-1. Simulations were run for an air
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cavity (µa=µs’=0) and an attenuating cavity with matching index of refraction (µatt=05, 0.05
cm-1), as well as for a water filled cavity. Simulations were also run for µs’=2 cm, 10 cm, 20 cm,
and 40 cm. The resulting fluence data from these simulations did not display any change in the
relationships observed in Figure 4.16-Figure 4.18 with changing µs’. For this reason we focus on
the results from one set of simulations with changing absorption in the surrounding tissue.
We observe, as for an air cavity, the scattered fluence is uniform at the cavity wall at all
angles. With increasing surface area (SA), here equal to S/4πr2, the total fluence at the cavity
wall decreases as 1/SA. Our results also demonstrate that the introduction of a non-air medium
into the cavity decreases both total and the scatter fluence. We observe that, as expected, when
attenuation is present, the scatter fluence decreases from that of an air cavity. And as
attenuation increases, scattered fluence accordingly decreases. Furthermore, eqn. ( 4.39 )
correctly predicts this change in fluence caused by attenuation. The symmetry of a
homogeneous sphere is the simplest cavity scenario to simulate. It remains to be seen if the
relationships that hold for a sphere will hold for a cavity with less symmetry.
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Figure 4.16: Φs/S over angle at spherical cavity boundary, MC results compared to empirical solution for different µatten
Scattered fluence rate per source power as a function of angle, for a centrally located source in at cavity wall of radius=10 cm, MC results compared to empirical equation, eqn.
.( 4.39 )
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Figure 4.17: Φs over angle at spherical cavity boundary, MC results compared to empirical solution for different µatten
Scattered fluence rate as a function of angle, for a centrally located source in at cavity wall of radius=10 cm, MC results compared to empirical equation, eqn.( 4.39 )
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Figure 4.18: Φs over angle at spherical cavity boundary, MC results compared to empirical solution for different µatten
Scattered fluence rate as a function of angle, for a centrally located source in at cavity wall of radius=10 cm, MC results compared to empirical equation, eqn.( 4.39 )
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Figure 4.19:: Scattered fluence as a function of surface area for a spherical air cavity
The scattered fluence was calculated using eqn. ( 4.39 )
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Figure 4.20: Scattered fluence rate per source power as a function of surface area for a spherical cavity with µattn=0.005, µs’=10
The scattered fluence was calculated using eqn.( 4.39 )

121

φ φs vs Surface Area: Spherical Cavity, µs’=10,
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Figure 4.21: Scattered fluence rate per source power as a function of surface area for a spherical cavity with µattn=0.05, µs’=10
The scattered fluence was calculated using eqn. ( 4.39 )
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4.5.4 Spherical Cavity MC Results for an off-center source
The same MC simulation method used in 4.6.1 was applied once more, only this
instance the light source was placed at 5 cm from the cavity center along the y-axis. Our aim was
to verify that not only is scattered fluence in the cavity uniform along the cavity boundary at all
degrees for a centrally located source, but also is also uniform when the light source is placed in
an off-center location (see Error! Reference source not found.Figure 4.14). 105 photons were
launched for µa=0.5 cm-1, and µs’=5, 10, 15, 25, and 40 cm-1. We observe that indeed the
scattered fluence is independent of source position and remains uniform at the cavity wall (see

Figure 4.23).
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Figure 4.22: Schematic of sphere with the light source off center at (0,5,0)

Figure 4.23: Scattered fluence rate per source power from MC simulation for an off-center source compared to
analytic solution.
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Note that not only is the scattered fluence uniform, but is also the same for the corresponding simulations run for a
centrally located source.

4.7 Ellipsoidal Monte Carlo Simulations
4.7.1 Monte Carlo Methods for an Oblate Ellipsoidal Cavity
The same MC simulation code used in 4.6.1 was applied for an oblate ellipsoid, where
one axis of symmetry is lost compared to a sphere (see Figure 4.24). The empirical solution for
fluence in a sphere (see eqn.( 4.37 ) is a function of the surface area, SA, of the cavity (for air):
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The surface area of an oblate ellipsoid is given by the following:
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Where a and c are the semi-principle axes of the ellipsoid (with a>b=c defining an oblate
ellipsoid) and e is calculated by the following:
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For an ellipsoidal cavity with an attenuating medium eqn.( 4.41 ) becomes:
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Where ravg is the average between the semi-major axis, a, and the semi-minor axes, b
and c:

?\Õ

}
.
3
125

( 4.45 )

The total fluence, with r representing the position from the source is then:

( 4.46 )

The multiple scattering of the photons was handled in the same manner as described above for
the spherical cavity.
ty. However, because of the loss of symmetry along one axis, a uniformly
distributed random number generator chose the angle the photon was scattered
scattere off the cavity
wall beyond the first two times a photon scattered off the cavity wall
wall,, should the photon be
scattered back into the cavity. This method was chosen because without symmetry in all
directions it becomes impossible to determine the following scattering angle.

Figure 4.24: Visualization of ellipsoidal cavity
(a)Visualization
Visualization of the ellipsoidal cavity used for simulation, with the geometry normalized to outer semi-major
semi
axis
(20 cm). (b) The ellipsoidal cavity used in this study is an oblate ellipsoid, where the two semi
semi-major
major axes are equal
with the semi-minor axis< semi-major
major axes. A cross section of the ellipsoidal cavity is depicted here along the semisemi
minor axis. (c)
c) Cross section of the cavity along the semi
semi-major axis.

126

4.7.2 MC Results for an Ellipsoidal Cavity
The MC simulations presented here were performed for an ellipsoid of semi-major axis
10 cm and semi-minor axis of 5 cm (this is, by definition, an oblate ellipsoid). 108 photons were
run for each simulation. The absorption coefficients of the surrounding medium are µa= 0.01,
0.05, and 0.1 cm-1, while the reduced scattering coefficient was kept constant at µs’=10 cm-1.
Simulations were run for an air cavity and an attenuating cavity (µatten=0.005 and  cm-1). The
voxel size of the geometry was 1 mm3. As with the spherical cavity simulations, simulations were
run for changing µs’ as well but we focus on one typical dataset. Again the scatter fluence is
found by subtracting P/SA from eqn.( 4.3 ) where P represents the power of the light source.
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Figure 4.25: Scattered fluence rate per source power (fs/S) at the ellipsoidal cavity boundary as a function of angle, for a centrally located
source, in an ellipsoidal cavity. MC results compared to values from eqn. ( 4.41 )
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-1

Figure 4.26: φs rate per source power at the wall of an air cavity vs surface area
area: MC results compared to empirical solution, eqn.( 4.44 ) for µs’=10.0 (cm )
-1

Where the fluence was normalized by dividing the results by maximum value for fluence for µa=0.01 (cm )
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Figure 4.27: Scattered fluence rate per source power at the boundary of an ellipsoidal cavity as a function of angle. Scattered fluence rate,
for a centrally located source, in an ellipsoidal air cavity. MC results compared to values from eqn. eqn.( 4.46 ).
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-1

Figure 4.28: : φs rate per source power at the wall of an air cavity vs surface area: MC results compared to empirical solution, eqn.( 4.44 ) for µs’=15.0 (cm )
-1

Where the fluence was normalized by dividing the results by maximum value for fluence for µa=0.01 (cm )
.
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4.8 Spherical Cavity Phantom Study
This study presents the results of an extensive phantom study that uses different sized
acrylic spheres and optical properties (both absorption and scattering). An isotropic detector
measured the fluence at the inner cavity wall. These measurements are compared to fluence
calculations using eqn.( 4.33 ).
The fluence as a function of angle along the cavity wall (Figure 4.28) agrees well with
eqn. ( 4.33 ), but the analytic solution for the total fluence at the cavity wall overestimates the
fluence compared to the MC results (Figure 4.28) for total fluence as a function of surface area.
This indicates a need to modify the analytic solution, either numerically based on simulation
results or via a different analytic approach. The results of these simulations do verify that the
total fluence at the cavity wall decreases cavity surface area as 1/SA regardless of cavity
symmetry.

4.8.1 Experimental Setup
The experimental setup for dose verification in a phantom used four different cavity
geometries (three spheres of radius=4.14, 5.46, and 7.78 cm) submerged in solutions of varying
optical properties. Two phantom treatments were conducted using the navigation system with
human torso geometry submerged in a solution of μa=0.78 cm-1 and μs’= 11.2 cm-1. A contour
and detector positions were measured twice using the contour navigation tool. Treatments
were performed for a period of five minutes each at a power of 3 W at 70% efficiency. The light
source position on the treatment wand was determined using the method described in section
5.2.1. All data was processed using programs developed in MatlabTM. Black India ink was used
for the absorption component and 20% concentration IntralipidTM was used for the scattering
component. IntralipidTM has been shown to produce scattering similar to that observed in
biologic tissues[86, 141] while the absorption spectra of the concentration of black ink used is
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similar to that of hemoglobin.
For each sphere, an isotropic detector was placed on the inside cavity wall and another
placed on the outside cavity wall to measure fluence monitored by an in-house made dosimetry
system (see Figure 4.29).

Figure 4.29: In-house built dosimetry system to measure fluence

An isotropic light source was used for the spherical cavities and a cylindrically diffusing light
source was used for the human torso geometry, both at 730 nm, at a power ranging from 1-2 W
(see Figure 4.30 for setup schematic, and Figure 4.31 for photos of the various setups). Each
cavity was submerged in a solution of nine different optical property combinations (μa=0.1 cm-1,
0.5 cm-1, 1.0 cm-1, μs’=2 cm-1, 10 cm-1, 20 cm-1) for each cavity condition (air, water, and
attenuating solution). Optical properties were measured using a motorized parallel catheter
system described previously in [11, 24], with the detector and source at 3 mm separation and
the detector moving an overall distance of 5 mm. For each solution, optical properties were
measured three times and fluence measured five times, with the resulting value of optical
properties and fluence being the average of the measurements respectively. For each solution
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combination, the light source was placed at both the center o
off the cavity and at an off-center
off
location in order to observe source location affects on fluence at the cavity wall. Measurements
were made in darkened room to prevent overhead lights from affecting overall fluence levels
while cavities were submerged in solutions contained in clear plastic containers.

(a)

(b)
Figure 4.30: Schematics for experimental setup of phantom study
(a) Schematic of experimental setup for a spherical cavity. Optical properties were measured three times before the
light source was placed within the cavity. (b) Schematic of experimental setup for the human torso geometry. The
“radius” of this geometry was
as determined by measuring the volume of the cavity and treating the cavity as a sphere.
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(a)

(b)

(c)
Figure 4.31: Setup for spherical cavity and torso phantom study
(a) and (b) Setup for spherical cavities submerged in solution. Note the parallel ccatheter
atheter system on the left of Figure
4.31a used to measure the optical properties of the solution. (c) Setup for the human torso phantom submerged in
solution with a cylindrically diffusing light source located at the center of the cavity
cavity.
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4.8.2 Results for Spherical Cavity Phantoms
Figure 4.32-Figure 44.34 display the results from the spherical cavity measurements for
spheres of varying radius. For a spherical air ccavity,
avity, there is good agreement between the
averaged measured fluence values and the calculated values (calculated using Eqn.( 5.2 )). As
the absorption coefficient of the solution surrounding the cavity increases we see the expected
decrease in fluence flatten out. We also observe the expected overall increase in observed
fluence with increasing reduced scattering. Once a medium other than air is introduced into the
cavity,
ity, this agreement begins to break down, with the theory overestimating the fluence. These
results are independent of cavity size.

(a)

(b)

(c)
Figure 4.32:: Spherical air cavity phantoms measured fluence ccompared
ompared to analytic solution
(a-c) Fluence as a function of µa for μs’=2 (red), 10 (blue), and 20 cm-1 (green).. Fluence calculated using ( 5.1 ) is
represented by a solid line.
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(a)

(b)

(c)
Figure 4.33: Spherical water cavity phantoms measured fluence compared to analytic solution
(a-c) Fluence as a function of µa for μs’=2 (red), 10 (blue), and 20 cm-1 (green).. Fluence calculated using ( 5.1 ) is
represented by a solid line.
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(a)

(b)

(c)
Figure 4.34:: Spherical cavity with attenuating medium phantoms measured fluence compared to analytic
ana
solution
(a-c) Fluence as a function of µa for μs’=2 (red), 10 (blue), and 20 cm-1 (green).. Fluence calculated using ( 5.1 ) is
represented by a dashed line.
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4.9 Light Fluence as a function of optical properties
Our MC simulations consider on an isotropic point source, or a pencil beam that is
convolved to simulate isotropic point source. In reality, the fluence is also affected by the type
of light source: linear, planar, and point sources. In addition to the effects the type of light have
on the fluence, whether multiple scattering occurs becomes important in determining the
fluence. Furthermore, the effect of optical properties becomes even more pronounced on
fluence inside the tissue itself. Figure 4.35a-c shows the light fluence rate, normalized to P/4πr2,
vs. µeff for a range of µs’ between 2 and 20 cm-1 for a multiple scattering (MS) point source inside
a 10 cm radius sphere at 0.5 cm depth. Comparing the MS point source (dashed-dotted lines) to
the planar source (dashed line) at the same depth in tissue (0.5 cm), the former is 3–7 times
higher than the later, depending on the optical properties. This increased value is due entirely to
the effect of multiple scattering, with minor influence due to the curvature of the 10 cm sphere
compared to that of the flat semi-infinite geometry.
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(a)

(b)

(c)

(d)
Figure 4.35: Fluence versus µeff for different light sources

Fluence rate, normalized to in-air fluence rate, versus µeff for linear, point sources inside an infinite medium, planar
light sources (dotted line) on a semi-infinite medium below an air-tissue interface, and point source with multiple
scattering (MS) inside a spherical cavity of 10 cm radius at 0.5 cm from the light source (for point or linear sources) or
1
0.5 cm depth in tissue (planar or MS point sources) for µs’= (a) 2.0, (b) 10.0 , (c) 20 cm . (d) φ/φair in a spherical cavity
at the air-tissue boundary.

From our MC simulations, we are able to consider how scattered fluence (Figure 4.36) at
the cavity boundary is a function of the optical properties of the surrounding medium. We used
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the MC results from Section 4.3.3 for a spherical air cavity with a 10 cm radius and a centrally
located source to observe how the fluence changes with µeff=(3µaµtr)1/2. The scattered fluence
was calculated for the corresponding µeff=(3µaµtr)1/2 using eqn.( 4.33 ) for an isotropic point
source. For each µs’ we see a unique curve when plotted against scattered fluence (also
observed in Figure 4.35). The agreement between theory and the MC results begins to diverge
at low µeff, which corresponds to low µa. The χ2 values of Figure 4.36 is 0.0494.

Figure 4.36: Scattered fluence at the cavity wall vs µeff for a spherical air cavity of radius 10 cm
Scattered fluence is plotted for the optical properties listed in Table 4.1 and using eqn. ( 4.33 ) for the analytic
solution.
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Figure 4.37: Scattered Fluence versus µeff for the minimum and maximum values of measure optical properties
Scattered fluence calculated using data from Table 3.4, Table 3.5, Table 3.6, and Table 3.7 and eqn.( 4.33 ).
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While our work focuses primarily on using MC simulations to determine the fluence in a
cavity, finite element models (FEM) is another m
method
ethod used to model the fluence. A simple FEM
simulation was run for an air cavity of radius=10 cm. The model was given the diffusion
approximation equations and boundary conditions discussed in chapter 2 to solve for the
fluence in the medium surrounding the cavity (Figure 4.38).
). This method again verifies that
scattered fluence is uniform at the cavity boundary for homogeneous optical properties,
properties
regardless of source location.

(a)

(b)
Figure 4.38: Depiction of FEM solution for an air cavity
-1

(a) Fluence for a centrally located source, (b) fluence for a source located at x=5 in an air cavity with µa = 0.3 cm ,
-1
µs’=14 cm , r = 10 cm

The MC simulations developed here do not consider how fluence is affected by
inhomogeneous optical properties in the surrounding medium. As observed from our results in
chapter 3, the optical properties in the thoracic cavity vary grea
greatly,
tly, and how this great variation
affects total and scattered fluence is unknown. The MC simulation developed for attenuation
has the potential to assign different optical properties to each voxel of the system. Without an
analytic solution for this scenar
scenario,
io, the results from such a simulation would need to be verfied
both by FEM and by phantom studies before an empirical formal could be developed. In a brief
study, we ran a FEM for a spherical air cavity where half the cavity had a uniform range of
optical properties from 0o to 180o. Just from this simple FEM run, we see that inhomogenous
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optical properties have a significant effect on fluence in the surrounding tissue. In future studies,
a relationship between this change in optical properties and fluence both in the cavity and in the
surrounding medium should be explored.

Figure 4.39: FEM fluence results for changing optical properties
o

µa went from 0.01-1.0 in 0.01 increments over 180 , µs’ went from 2.0-10 in 0.5 increments over 180
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Chapter 5

Fluence Modeling and IR Navigation
The preceding chapters discuss several key elements of implementing more accurate
and efficient light fluence delivery during PDT mediated plural PDT in the thoracic cavity. The
spectroscopic evaluation of the thoracic cavities if patient enrolled in the Phase I study at UPHS
demonstrate the wide ranging variety of the optical properties both throughout a single thoracic
cavity and between patients. The fluence modeling developed and verified via MC simulations
provide an analytical solution for light distribution within a cavity and in the surrounding
medium, given a set of optical properties. Utilizing our spectroscopic data in our fluence models
we have the potential to calculate patient specific light fluence, a novel approach to pleural PDT.

5.1 Introduction
In collaboration with Drs. X. Liang, C. Chang, and T.Zhu, B. Lui and Michele Kim, an
infrared (IR) tracking camera was used to develop a treatment guidance system. This tracking
system provides the missing piece of the puzzle of real-time, patient-specific PDT light fluence.
This system tracks obtains a contour of the patient’s thoracic cavity during surgery and then
tracks the position of the light source relative to the cavity walls. With this position data, we can
improve the uniformity of light treatment[42]. Current light fluence protocol provides only
discrete light fluence information; seven isotropic detectors are sutured at strategic points in
the thoracic cavity[112, 113]. The detected fluence of these detectors is displayed to clinician in
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real-time,, and once all seven detectors reach the prescribed light fluence,, the light treatment
treatmen is
ended. Using the IR tracking system, in contrast, provides guidance to the clinician over the
entire cavity in 3D, when real
real-time light source position data is displayed. The initial
development and application of this tracking system is presented in the following sections.

5.2 Infrared Camera System
5.2.1 Instrumentation
This navigation system is based on an IR camera (Polaris® Spectra, North Digital Inc.,
Waterloo, Canada), which has been used in medical fields such as spinal surgery, position
control of surgical robot, and abdominal therapy intervention [142, 143]. Utilizing
izing the IR camera
shown in Figure 5.1a,, the navigation system is able to obtain a contour of the patient’s thoracic
cavity, and track the position of the light source during treatment in 3D.. The accuracy of the
system was ~0.5 mm in 3D, and the maximum volume for the system was ~ 205 ° x 186 ° x 147
cm3, which was sufficient for operations on our patient population. The tracking tool in the
navigation system is a rigid body built on passive reflective markers (Figure 5.1
1b). The markers
are used as the tracking target for the navigation system to track motion of the light source.
sourc

Figure 5.1: IR tracking system and torso phantom
Photographs of (a) pleural PDT navigation camera, (b) tracking tool for the navigation system, and (c) human-shape
human
phantom.

146

Once the tracking tool is in the working volume, the IR camera system starts to track the
position of the markers in 3D, and track the position of the tip of the rigid body by applying a
vector to the position of the markers. The tip position data are transferred to a computer at a
rate of 20-60 Hz, and can be displayed in real-time. When taking a surface contour in phantoms,
the tip of the tracking tool is used to gently slide against the inner surface. The tracking tool tip
positions over time represented the surface positions or raw contour data in 3D, based on which
the inner surface contour is determined, given enough position samples. Before this system was
implemented and further developed in the operating room, extensive phantom studies were
conducted in order to determine wand design and overall procedure.

5.2.2 Treatment Guidance Procedure
The procedure of the image-guidance system for pleural PDT is shown in Figure 5.2. Two
positioning wands were used in this procedure to complete the image guidance. One wand was
used for taking detector and treatment surface contour, while the other one was used for
tracking the light source position during PDT treatment. They are referred to as contour wand
and treatment wand respectively. Both wands are calibrated to locate their tip positions by
pivoting them around a fixed point. Then an optimization algorithm was used to determine the
shift between the treatment wand tip and the laser point source. The contour wand is then used
to locate the seven detectors on the cavity surface, and also to determine the cavity contour.
When the PDT treatment begins, the treatment wand is used and the light fluence distribution
on the cavity surface is calculated simultaneously from the position data. The scattered portion
of light fluence is given by[144]:
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where S is the light source (W), As is the surface area of the cavity, Rd is defined in Eqn.( 2.35 ),
and f is the fraction of open area to the surface area of the cavity. The total fluence then
becomes:
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( 5.2 )

Where r is the distance between the cavity wall and the light source. Using Eqn.( 5.2 ) the light
fluence can be calculated in real-time to achieve a uniform light fluence in the cavity. To verify
the image-guidance procedure, the isotropic detectors sutured to the thoracic cavity surface are
used to compare the calculated fluence from the tracking data with the detectors
measurements at several positions.
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(a)

(b)
Figure 5.2:: Schematics for treatment procedure and optimization algorithm

(a) Schematics for the treatment procedure for image guided treatment. (b) Schematics for the optimization
algorithm to determine iteratively the position of the laser sou
source relative to the wand tip (λm).

5.3 IR Camera Study for Human Torso Cavi
Cavity
This study is a continuation of the phantom study discussed in section4.8. The
experiment setup was similar to that of section 4.8.1, with the human torso submerged in a tub
of a liquid solution with optical properties similar to that of tissue. Position
n data of the
treatment is collected from the IR navigation system while concurrently light distribution
measurements were made using t isotropic d
detectors.
etectors. These measurements were compared to
fluence calculations made using data from the IR navigation sys
system
tem to verify our light
distribution theory (using eqn. ( 5.1 )) is correct and applicable in patient-like
like settings.

5.3.2 Results: Human Torso Cavity
The human torso phantom picture in Figure 5.1c was submerged in a solution of varying
optical properties, and the fluence experienced at the cavity was measured using two isotropic
detectors. Figure 5.3 displays th
the
e results of these measurements compared to the calculated
fluence, treating the torso cavity as a sphere of the same volume. Unlike the spherical cavity,
there appears to be greater agreement between theory and observation for a water cavity as
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compared to the air cavity.
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(b)

(a)

(c)
Figure 5.3:: Averaged measured fluence per source power for human torso phantom compared to analytic solution.
solution The
averaged fluence measured (circles) compared the fluence calculated (dashed line) for the human torso cavity for an (a) air
cavity, (b) water cavity, and (c) attenuating medium cavity.
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5.3.3 Navigation System Application to human torso phantom
Using the procedure presented in [145],, two treatments were conducted using the human torso
cavity. Using the position tracking data coupled with Eqn.( 5.2 ) where r is the distance between the light
source
ource and the cavity wall (the location of which is determined using the contour displayed in Figure
5.5a),, a comparison is made between measured and observed fluence. By including the scattered light in
the calculation, greater agreement is achieved between observation and theory, as seen in Figure 5.5.

Figure 55.4: Contour of human torso taken with IR camera
The walls of the phantom are represented by blue, the movement of the light source is represented by pink, and the two
isotropic detectors measuring fluence are represented by green squares.
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(a)

(b)
Figure 5.5:: Results for IR system applied to torso phantom. (a-b)) the overall fluence rate measured as a
function of time (red) compared to the direct light calculation (blue) and the direct plus scattered light
calculation (green).
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The results for a spherical air cavity are in good agreement with the theory presented in
Eqn. ( 5.2 ). Upon the introduction a medium within the cavity, however, this agreement begins
to break down and the theory consistently overestimates the amount of fluence experienced by
the cavity wall. Further investigation is needed to determine the cause of this disagreement.
When considering a cavity of arbitrary geometry such as an empty human torso, the geometry
can effectively be approximated as a sphere of the same volume and still achieve good
agreement between fluence observations and calculated fluence. Again, with the introduction
of an attenuating medium in the cavity, our theory overestimates the fluence at the cavity wall.

5.4 Recent Developments
The development of this guidance system is ongoing and the result of the collaborative
efforts of the entire PDT group at UPenn. The earliest stages of development, worked on by Dr.
Chang, Dr. Liang, Dr. Zhu, and myself, included wand design, methods of light source
determination, and proper procedure in the OR. The phantoms studies discussed above aided in
verifying light fluence calculations using this system. The most recent developments are the
product of the work of Michele Kim, Baochang Liu, Xing Liang, and Tim C. Zhu and are included
here to present readers with the most recent developments of this ongoing project.

5.4.1 Improved real-time determination of light source position [146]
The light source is placed inside an ellipsoidal balloon that is filled with an IntrallipdTM
solution. This setup makes it challenging to accurately determine the location of the light source
in relation to the trip of the treatment wand. Several generations of tools were developed to
address these issues. The most recent tool uses eight different isotropic detectors in known
locations (Figure 5.6), as opposed to the first generation of light source positioning tool, which
used one detector and required the measurement of eight different positions (see Figure
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5.6a)[42]. With this new light source position tool, a reference wand is used to measure the
relative positions of the detectors in the OR (see arrow in Figure 5.6). This new tool provides a
faster and more accurate method of determining the light source position.

(a)

(b)
Figure 5.6: Light source position tool

Laser source position determination using (a) a single isotropic detector and (b) modified laser source calibration tool
that incorporates 8 isotropic detectors so that all 8 measurements can be performed at once. The arrow points to the
positioning wand for the tool.

5.4.2 Real-time feedback of light fluence calculations
In order to provide real-time feedback to the measured values, Xing Liang and Baochang
Liu developed another MatlabTM-based GUI to display the calculated light fluence on a 2D
unwrapped surface. OpenIGTLinkTM was used to provide a platform communicating between the
NDI Polaris camera and a PC. The light source position data were acquired at a frequency of 20
Hz from the NDITM data acquisition driver. When the PC receives the light source position data,
MatlabTM was used to calculate the cumulative light fluence on every point of the pleural cavity
contour, and to display/update the unwrapped light fluence distribution map at the frequency
of 20 Hz. In the light fluence distribution map, 3D points on the pleural cavity contour were
unwrapped into 2D φ-z maps, given the condition that on each x-y plane of the cavity contour,
there is only one point for each angle φ, where φ=atan(y/x). Calculation is based on the direct
light term of Eqn.( 5.2 ) and displayed the cumulative light fluence in real-time during treatment.
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Chapter 6

Conclusions and Future Work
6.1 Summary
The goal of this work was to address to key factors in PDT light dosimetry for treatment
in cavity-like geometries: the modeling of light dose in a cavity and the determination of in vivo
optical properties via spectroscopic methods. Prior to this work, understanding and reliable
modeling of how applied light during PDT is affected by treatment in a cavity was developed
only for spherical symmetric cavities. In vivo optical properties of both the canine
interperitoneal and human thoracic cavities were unknown.
Building upon the existing theory of the diffusion approximation to the radiative
transport equation, we successfully verified Willem Star’s theory for total and scattered fluence
in a spherical cavity with no attenuating medium. We built on this work by creating MC
simulations of spherical cavities with air, attenuation, and off-center light sources to verify the
scattered fluence at the cavity wall is uniform, regardless of attenuation or light source position.
We went further to demonstrate that scattered fluence is not only uniform for spherically
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symmetric cavities, but also oblate ellipsoids. The results of our simulations indicate to us that
the scattered fluence is a function the cavity surface area. This result hold much promise as the
IR navigation system developed and presented here will be able to determine the surface area
of a patient’s thoracic cavity in real-time. This tool, in combination with these results, may be
further developed to calculate the patient-specific light dose in real-time during treatment.
An equally important aspect of this work was the successful in vivo measurements of
canine and human tissues during treatment. As shown in the first chapter, in vivo human data of
this nature is very limited and the data presented here does much to expand what is currently
available in the literature. The spectroscopy data not only informs our light fluence model but
also provides vital information concerning tissue oxygenation, drug concentration, and total
hemoglobin levels in treated tissue. The high variability between patients and tissue types
indicates the need for real-time in vivo spectroscopy to fully and most accurately inform our
fluence model; work that is already being explored.
Add a paragraph to discuss the magnitude of scatter fluence for the range of optical
properties observed above.
Further developing a fluence model for a completely arbitrary treatment cavity
geometry, and combining this model with the IR navigation remains to be completed. Once this
is accomplished, combined with real-time spectroscopy holds significant potential to implement
a patient-specific PDT light dose and improve PDT efficacy overall.
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Appendices
A.1 P3 Approximation for a Semi-Infinite Medium
The P3 approximation, which is used to determine the Green’s function of the radiative
transport equation, was developed to overcome the two major limitations of diffusion theory:
µa << µs’ and is only valid for source-detector distances larger than one mean free path. Recall
the mean free path is 1/(µa+µs’). We present the following derivation developed by Hull and
Foster[68] for the P3 approximation.
The Boltzman equation is a widely accepted method of describing light propagation in turbid
media. Here we use the time independent Boltzmann equation as all our work assumes a steady
state solution:
1 t, ̂ , ×
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(A. 1)

Where L is the radiance at a position r in direction s and has units of power per unit area per
unit solid angle. The function f is the scattering phase function, describing the probability a
photon with direction s will be scattered into direction s’. Equation (A. 1) is difficult to solve
analytically and several different approaches to determine a solution have been developed.
Here, we consider a Pn approximation, expanding up to n=3. The angular quantities of eqn.(A. 1)
are expanded in spherical harmonics Ylm:
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Where φlm is the moment of radiance and σlm is the moment of the source distribution. Here,
the fluence is defined as the isotopic component of the radiance, which is given by:
.66
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(A. 3)

We assume that the scattering amplitude is a function of the scattering angle, but independent
of the spatial location and direction of the incident light. The scattering phase function can then
be expressed by a series of Legendre polynomials:
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For an infinite slab geometry, the radiance is dependent on the z coordinate and the cosine of
the angle between the z axis and the observation direction ̂ . This quantity will be referred to as

η. Equations (A. 2) and (A. 4) are then expanded to the following:
P, Ø
P, Ø
̂ · ̂ 

3

2  1

+
 0
3

4"

2  1

+
 0
3

4"

2  1

+
 0

# Z P 9 Ø

4"

159

# Ù P 9 Ø

# $ P 9 ̂ · ̂ 

(A. 5)

Where Pm is a Legendre polynomial of order m and ϕm and qm are the moments of radiance
source distribution respectively. We use the expressions in eqn. (A. 5) in eqn. (A. 1) by
multiplying by Pl(η) and integrating over all solid angles, resulting in a first order linear ordinary
differential equation:
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Expanding (A. 6) to l=3:
? Z6

1
Z 
3 6

1
Z 
5 4

4


%


 Z4 

1
Z 
7 %

Ù6 ,

2
Z4  Z% 
3

3
Z%  Z' 
5
'


Z'

Ù4 ,
Ù% ,

(A. 7)

Ù' ,

where the prime denote differentiation, µa(l)=µa+µs(1-gl), and µt(0)=µa. To find a complete
solution for the radiance in the P3 approximation, we determine four single-exponential
solutions to homogeneous version of eqns. (A. 7) for the source-free regions for the moment of
radiance. We assume a solution for ϕl of the form:
Z/ P
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Substituting eqn.(A. 8)into eqns.(A. 7) for l=0,1,2,3:
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By requiring the determinants of eqns.(A. 9) to vanish, nontrivial solutions for ν:
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The values for Ý ¼ were previously determined by Star[147] and Boas et al.[134]. The coefficients
F/Û are determined by solving eqn. (A. 9) which are related to F6Û and are functions of the

optical properties of the medium, hl(νj):
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Recall that the h0(νj) are equal to unity.
The radiance in the source-free region of the media with planar symmetry is given by:
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Where ϕl(z) is given by eqn.
eqn.(A. 8), the attenuation coefficients νj are given by eqns.(A.
eqns. 10) and
constants

defined by eqns.
eqns.(A. 12),(A. 13), and (A. 14). The constants

are determined by

the source distribution and boundary conditions
conditions.
For a slab of infinite length and finite width of thickness 2b and a homogeneous distribution of
isotropic sources, we can determine the fluence using the above approach. First, we take the
limit as the slab width goes to zero, the source strength goes to infinity, and the product 2q0b is
equal to unity (unit source per unit area).
As observed in Figure A. 1,, there are two regions of interest: the internal region, where |z|<b,
and the external region, where |z|>b. In the internall region, all possible values of ν are
permissible (see eqn.(A. 10
10)) while in the external region only decaying solutions, meaning
are permissible.

Figure A. 1: Semi--infinite geometry slab used in the derivation of the P3 approximation
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By symmetry about the z=0 axis, and the hl(νl) are of odd parity with respect to ν for odd l and
even parity for even l, the following expressions are obtained for the internal region:
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We are interested in the external region coefficients C and D, which describe the radiance
outside the source region. At the boundaries P

¼, we require continuity of each moment of

radiance and assume an isotropic source (ql=0 for all - â 1). The solution to eqn.(A. 7) then

becomes:
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With these conditions, we solve the following system of equations at the boundary for the
coefficients C and D:
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To conclude, the fluence for a semi-infinite medium with an infinite place source is:
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Where the coefficients C and D are defined in eqn. (A. 20).

A.2 Absorption Spectra of HPPH in Solvents
A.2.1 Methods
The absorption spectra of HPPH used in the Phase I study ongoing at UPenn was
measured using an Ocean Optics cuvette holder, our Avantes white light source, and our LNcooled CCD spectrograph. Two transfer fibers were connected by a variable attenuator and
carried the light from the source to the cuvette holder. The attenuator was adjusted prior to
measurements to prevent saturation of the CCD. Three different solvents were used: PBS,
dextrose-5, and “Solvenator”, a homemade detergent (SDS (10%)+NaOH(1%)+ddH2O(89%)).
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Solvents were measured at 0, 5, 10, and 20 minutes in two different cuvettes (for a total of eight
measurements). Between measurements each cuvette was removed from the holder and
replaced at the next time interval. Following these measurements, a solution of 1 ml solvent and
0.05 g of bovine serum albumin (BSA) for a 5% concentration of BSA was made (again,
measurements were made using two different cuvettes for each solvent-BSA combination for a
total of eight measurements). A solution of 1 ml solvent and 20 µL of HPPH (aqueous solution at
1.37 mg/ml) was then made and measured using the schema described above (four
measurements total for one cuvette). Following this series of measurements, a solution of 1 ml
solvent, 0.05 g BSA, and 10 µL HPPH was made and measured in a similar fashion. HPPH was
measured using the Eppendorf 10-100 µL (Serial No. 410455) pipette.
Emission spectra of two lasers were characterized using the same spectrograph and
overlaid on the absorption spectra of HPPH to determine a relative effectiveness.

A.2.2 Results
Measurements made over time were averaged and the standard deviation was found.
The error bars were created by taking (standard deviation)/(N1/2) where N is the number of
measurements made (N=8 for solvent-only and solvent+BSA measurements, N=4 for
HPPH+solvent and HPPH+BSA+solvent measurements). Table 1 lists the values of the raw data,
µa, and transmission with the corresponding standard deviations for 661 and 665 nm for
HPPH+BSA+solvent solutions and HPPH+solvent solutions.
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Figure A. 2: Overhead mercury lamp with known spectral peaks
Measurement of overhead mercury lamp (blue curve) overlaid with the known spectral peaks (vertical lines) of
mercury emission. There is good agreement (maximum deviation is ~0.5 nm) between the two spectra, indicating the
wavelength calibration for the spectrograph is co
correct.
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Table A. 1: Measurements of HPPH and HPPH solvents
HPPH+BSA

Peak (nm)

PBS
665.40

Solvenator
663.80

D5W
664.60

HPPH

Peak (nm)

PBS
665.00

Solvenator
664.20

D5W
664.60

Roswell

wv (nm)

µa

stdev

658

2.08E+00

2.61E-03

661

2.65E+00

2.63E-03

665

3.01E+00

3.15E-03

658

7.45E-01

2.16E-01

661

8.84E-01

2.93E-01

665

9.17E-01

3.11E-01

658

2.17E+00

8.04E-03

661

2.69E+00

8.68E-03

665

2.92E+00

9.87E-03

wv (nm)

µa

stdev

658

1.33E+00

9.28E-03

661

1.64E+00

8.91E-03

665

1.84E+00

9.31E-03

658

1.47E+00

1.31E-02

661

1.90E+00

1.18E-02

665

2.11E+00

1.04E-02

658

1.90E+00

1.34E-02

661

2.38E+00

1.34E-02

665

2.65E+00

1.22E-02

667.70
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Σ φ661/Σφ665

Σ φ658/Σφ661

Σ φ658/Σφ665

0.8912

0.8047

0.7172

0.9505

0.8542

0.8119

0.9208

0.8372

0.7709

Σ φ661/Σφ665

Σ φ658/Σφ661

Σ φ658/Σφ665

0.9012

0.8374

0.7547

0.9066

0.8229

0.7461

0.9002

0.8229

0.7487

0.8307

0.7774

0.6458

Figure A. 3: HPPH in different solutions

A.3 Verification of the wavelength of three B&W Tek diode lasers
A.3.1 Purpose
A new 665 nm diode laser was purchased from B&W Tek. A series of measurements
were done on both the new 665 nm and the existing 661 nm to quantify the emission spectrum
and power setting dependence.

A.3.2 Methods & Materials
The two lasers measured are listed in Table A. 1.. In each case, the laser being measured
as coupled to a 400 micron core, 0.39 NA optical cable (Thorlabs M28L02). The power out of the
fiber was measured using a thermopile power meter (Coherent LM
LM-10).
10). Care was taken to
ensure that the beam projected by the fiber under
under-filled
filled and was concentric with
wi the active area
of the detector. To measure the spectrum, the same fiber was coupled into one port of a 6-inch
6
integrating sphere (Labsphere). A second port, blocked from the first by a baffle (661 nm laser
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measurements were not blocked by the baffle), was coupled to an SMA patch cable, through a
manual attenuator (OZ optics), and into a CCD based spectrograph. The attenuator was adjusted
to prevent saturation of the detector. Multiple spectra were acquired at each power setting of
each laser to ensure that the spectrum was stable over time. Multiple spectra were also taken at
different slit widths to observe how sharp the spectral peak becomes. To verify the wavelength
calibration of the spectrograph, a measurement of the spectrum of the lab’s overhead mercury
lights was recorded.

A.3.3 Results
Figure A. 2 shows the correspondence between the measured spectrum of the overhead
mercury fluorescence lights (data) and known emission lines (vertical red lines). The maximum
different between known emission and measured emission is ~1.7 nm. Table A. 1 lists the
measured power, wavelength peaks, and FWHM for both the 661 and 665 nm lasers at different
powers. For both lasers, the wavelength peak gradually shifts higher in the spectrum as power
increases. The 661 nm displays a greater shift in spectral peak than the new 665 laser, which
shifts about ~0.5 nm (see Figure A. 4). In both cases, the wavelength measurements made with
the spectrograph were in agreement with rough measurements made with a handheld dial
monochromator.

169

Table A. 2: BWF-5-665 Laser

Power setting
(mA)
0.5
1
1.5
2
3
4
6
8

Total
power
(mW)
0.48
0.96
1.46
1.98
2.98
3.90
5.80
x

Peak center
(nm)

FWHM
(nm)

665.8
665.8
665.8
665.8
665.8
665.8
666.3
666.3

2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.6

Table A. 3: BWF-5-661 Laser

Power
setting
(mA)
0.5
1
1.5
2
3
4
6
8

(a)

Total
power
(mW)
X
X
X
X
X
X
X
X

Peak center (nm)

FWHM
(nm)

660.4
660.4
660.7
660.9
660.9
661.4
661.9
662.4

2.5
2.7
2.6
2.7
2.6
2.6
2.6
2.6

(b)
Figure A. 4: Measured spectra of the 661 and 665 diode lasers
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A.4.1 Presentations
J.L. Sandell3, J.C. Finlay, T. Zhu, J. Friedberg, K.A. Cengel, In Vivo Determination of Optical
Properties from Pleural PDT in Humans. 35th Annual Meeting. American Society for
Photobiology. June 12-16, 2010, Providence, RI.
J.L. Sandell, C. Chang, T.C. Zhu, Light Fluence Rate Calculation for Intracavity
Photodynamic Therapy. 52nd Annual Meeting. American Association for Physicists in Medicine.
Imaging General Poster Discussion. July 18-22, 2010. Philadelphia, PA.
J.L. Sandell, T.C. Zhu, J.C. Finlay, X. Liang. Monte Carlo Simulation of Arbitrary
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Jarod C. Finlay; Julia L. Sandell; Timothy C. Zhu; Robert Lewis; Keith A. Cengel; Stephen M. Hahn:
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using MC simulation Proc SPIE 7886: 788619, Feb 2011.
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navigation system for real-time treatment guidance of pleural PDT. Proc SPIE 7886: 28860L, Feb
2011.
Julia L Sandell, Xing Liang, Timothy C. Zhu: Light dose verification for pleural PDT. Proc
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